<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81639</article-id><article-id pub-id-type="doi">10.7554/eLife.81639</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Structural characterization of human RPA70N association with DNA damage response proteins</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-286121"><name><surname>Wu</surname><given-names>Yeyao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1144-8508</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-286124"><name><surname>Fu</surname><given-names>Wangmi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-286122"><name><surname>Zang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-285346"><name><surname>Zhou</surname><given-names>Chun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9257-468X</contrib-id><email>chunzhou@zju.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00a2xv884</institution-id><institution>School of Public Health &amp; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Zhejiang</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shinohara</surname><given-names>Akira</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>05</day><month>09</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81639</elocation-id><history><date date-type="received" iso-8601-date="2022-07-05"><day>05</day><month>07</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-09"><day>09</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-07-15"><day>15</day><month>07</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.07.14.500000"/></event></pub-history><permissions><copyright-statement>© 2023, Wu, Fu, Zang et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Wu, Fu, Zang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81639-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81639-figures-v1.pdf"/><abstract><p>The heterotrimeric Replication protein A (RPA) is the ubiquitous eukaryotic single-stranded DNA (ssDNA) binding protein and participates in nearly all aspects of DNA metabolism, especially DNA damage response. The N-terminal OB domain of the RPA70 subunit (RPA70N) is a major protein-protein interaction element for RPA and binds to more than 20 partner proteins. Previous crystallography studies of RPA70N with p53, DNA2 and PrimPol fragments revealed that RPA70N binds to amphipathic peptides that mimic ssDNA. NMR chemical-shift studies also provided valuable information on the interaction of RPA70N residues with target sequences. However, it is still unclear how RPA70N recognizes and distinguishes such a diverse group of target proteins. Here, we present high-resolution crystal structures of RPA70N in complex with peptides from eight DNA damage response proteins. The structures show that, in addition to the ssDNA mimicry mode of interaction, RPA70N employs multiple ways to bind its partners. Our results advance the mechanistic understanding of RPA70N-mediated recruitment of DNA damage response proteins.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>RPA</kwd><kwd>HelB</kwd><kwd>BLM</kwd><kwd>RMI1</kwd><kwd>WRN</kwd><kwd>ATRIP</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>31971125</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Chun</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Structural characterization of human RPA70N association with a series of DNA damage response proteins reveals versatile protein interaction mechanisms that help to recruit DNA repair proteins to the damage site quickly and efficiently.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Replication protein A (RPA) is a heterotrimeric protein complex composed of the RPA70, RPA32 and RPA14 subunits (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib26">Fairman and Stillman, 1988</xref>; <xref ref-type="bibr" rid="bib82">Wood et al., 1988</xref>). It is the major eukaryotic single-stranded DNA (ssDNA) binding protein and has an affinity for ssDNA in the range of 10<sup>–9</sup>–10<sup>–10</sup> M (<xref ref-type="bibr" rid="bib5">Blackwell and Borowiec, 1994</xref>; <xref ref-type="bibr" rid="bib42">Iftode et al., 1999</xref>; <xref ref-type="bibr" rid="bib47">Kim et al., 1994</xref>; <xref ref-type="bibr" rid="bib46">Kim et al., 1992</xref>; <xref ref-type="bibr" rid="bib81">Wold, 1997</xref>). Several DNA-binding domains (DBD-A, B, C, D), which are also called oligonucleotide binding domains (OB), form the core ssDNA binding region (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib6">Bochkarev et al., 1997</xref>; <xref ref-type="bibr" rid="bib7">Bochkareva et al., 2002</xref>; <xref ref-type="bibr" rid="bib27">Fan and Pavletich, 2012</xref>; <xref ref-type="bibr" rid="bib30">Flynn and Zou, 2010</xref>; <xref ref-type="bibr" rid="bib57">Murzin, 1993</xref>; <xref ref-type="bibr" rid="bib89">Yates et al., 2018</xref>). Due to its high affinity for ssDNA, RPA is involved in almost all aspects of DNA replication, repair, and recombination (<xref ref-type="bibr" rid="bib12">Caldwell and Spies, 2020</xref>; <xref ref-type="bibr" rid="bib14">Chen and Wold, 2014</xref>; <xref ref-type="bibr" rid="bib28">Fanning et al., 2006</xref>; <xref ref-type="bibr" rid="bib42">Iftode et al., 1999</xref>; <xref ref-type="bibr" rid="bib54">Maréchal and Zou, 2015</xref>; <xref ref-type="bibr" rid="bib81">Wold, 1997</xref>; <xref ref-type="bibr" rid="bib94">Zou et al., 2006</xref>). It helps to protect ssDNA from nucleolytic degradation and prevents ssDNA entanglement by removing DNA secondary structures.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>RPA70N–peptide complex structures determined in this study.</title><p>(<bold>A</bold>).Linear domain diagram of the RPA heterotrimer. (<bold>B</bold>) Ribbon representation of human RPA70N from PDB 5EAY. L12 denotes the loop between β1 and β2, L45 is the loop between β4 and β5. (<bold>C</bold>) Surface representation of RPA70N from PDB 5EAY, showing the basic groove and the side pocket, with hydrophobic, positively and negatively charged atoms in yellow, blue and red, respectively, and other atoms in white. (<bold>D</bold>) Conservation of the human RPA70N sequence. (<bold>E</bold>) Most of the conserved residues in RPA70N are located at the basic groove region. (<bold>F–N</bold>) Ribbon representation of the RPA70N–peptide complex structures determined in this study displayed in the same view. RPA70N is colored in gray.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Data collection and refinement statistics.</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-81639-fig1-data1-v1.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Sequence alignment and omit maps of bound peptides (related to <xref ref-type="fig" rid="fig1">Figure 1</xref>).</title><p>(<bold>A</bold>) Alignment of human RPA70N-interacting motif sequences from different proteins. (<bold>B</bold>) Linker and peptide sequences used in RPA70N fusion constructs. (<bold>C–K</bold>) <italic>mFo-DFc</italic> electron density maps (green mesh) of RPA70N–peptide complex structures determined in this study contoured at 2.0 σ.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig1-figsupp1-v1.tif"/></fig></fig-group><p>In addition to its ssDNA binding function, RPA also serves as a beacon to recruit a plethora of protein factors that are involved in DNA metabolism, mostly through the RPA70N and RPA32C (winged-helix) domains (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib2">Awate and Brosh, 2017</xref>; <xref ref-type="bibr" rid="bib12">Caldwell and Spies, 2020</xref>; <xref ref-type="bibr" rid="bib28">Fanning et al., 2006</xref>; <xref ref-type="bibr" rid="bib54">Maréchal and Zou, 2015</xref>). The RPA70N domain adopts an OB fold with a five-stranded anti-parallel beta-barrel but has very weak ssDNA affinity (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="bibr" rid="bib43">Jacobs et al., 1999</xref>). Its primary role is to mediate protein–protein interaction with its basic and hydrophobic groove and a side pocket (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), as first shown by a series of studies of RPA70N interacting with p53 (<xref ref-type="bibr" rid="bib1">Abramova et al., 1997</xref>; <xref ref-type="bibr" rid="bib23">Dutta et al., 1993</xref>; <xref ref-type="bibr" rid="bib51">Li and Botchan, 1993</xref>). The groove is flanked by two protruding loops, namely L12 and L45 (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). The residues forming the groove and the side pocket are highly conserved, indicating that they are critical for RPA70N’s protein interaction role (<xref ref-type="fig" rid="fig1">Figure 1D and E</xref>; <xref ref-type="bibr" rid="bib88">Yariv et al., 2023</xref>). In the crystal structure of the RPA70N–p53 complex, the acid-hydrophobic peptide of p53 is shown to interact with the complementary basic and hydrophobic groove, mimicking ssDNA binding to OB domains (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib8">Bochkareva et al., 2005</xref>).</p><p>RPA70N binds to the p53 transactivation domain to coordinate DNA repair with the p53-dependent checkpoint control (<xref ref-type="bibr" rid="bib23">Dutta et al., 1993</xref>). RPA70N also binds to the N-terminus of ATRIP and is responsible for recruiting the ATR–ATRIP complex to DNA damage sites to initiate the cell-cycle checkpoint (<xref ref-type="bibr" rid="bib3">Ball et al., 2005</xref>; <xref ref-type="bibr" rid="bib58">Namiki and Zou, 2006</xref>; <xref ref-type="bibr" rid="bib93">Zou and Elledge, 2003</xref>). Later it was shown that RPA70N mediates the interaction of RPA with the MRN complex and the 9-1-1 complex to protect replication forks during the DNA damage response, through binding to MRE11 and RAD9 (<xref ref-type="bibr" rid="bib61">Oakley et al., 2009</xref>; <xref ref-type="bibr" rid="bib62">Olson et al., 2007</xref>; <xref ref-type="bibr" rid="bib64">Robison et al., 2004</xref>; <xref ref-type="bibr" rid="bib83">Wu et al., 2005</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2008b</xref>). Recently, studies identified Ewing Tumor-associated Antigen 1 (ETAA1) as a DNA replication stress response protein and an ATR activator, which interacts with both RPA70N and RPA32C (<xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>). Besides cell cycle regulatory proteins, many helicases that are involved in DNA repair interact with RPA70N (<xref ref-type="bibr" rid="bib2">Awate and Brosh, 2017</xref>). Both BLM (Sgs1) and DNA2 interact with RPA and form a complex to carry out long-range DNA resection during double-strand DNA break repair (<xref ref-type="bibr" rid="bib13">Cejka et al., 2010</xref>; <xref ref-type="bibr" rid="bib33">Gravel et al., 2008</xref>; <xref ref-type="bibr" rid="bib59">Nimonkar et al., 2011</xref>; <xref ref-type="bibr" rid="bib92">Zhu et al., 2008</xref>). RPA was proposed to recruit both DNA2 and BLM through RPA70N, stimulating the helicase activity of BLM while enhancing the nuclease activity of DNA2 by removing DNA secondary structures (<xref ref-type="bibr" rid="bib10">Brosh et al., 2000</xref>; <xref ref-type="bibr" rid="bib20">Doherty et al., 2005</xref>; <xref ref-type="bibr" rid="bib59">Nimonkar et al., 2011</xref>; <xref ref-type="bibr" rid="bib91">Zhou et al., 2015</xref>). WRN, HelB and FancJ also bind to RPA through RPA70N, and the presence of RPA greatly enhanced their helicase activities (<xref ref-type="bibr" rid="bib9">Brosh et al., 1999</xref>; <xref ref-type="bibr" rid="bib20">Doherty et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Guler et al., 2012</xref>; <xref ref-type="bibr" rid="bib36">Gupta et al., 2007</xref>; <xref ref-type="bibr" rid="bib41">Hormeno et al., 2022</xref>; <xref ref-type="bibr" rid="bib67">Shen et al., 1998</xref>; <xref ref-type="bibr" rid="bib68">Shen et al., 2003</xref>; <xref ref-type="bibr" rid="bib73">Suhasini et al., 2009</xref>; <xref ref-type="bibr" rid="bib77">Tkáč et al., 2016</xref>). Moreover, many other proteins that are involved in DNA repair and replication also interact with RPA70N. For example, the RMI1 component of the BTR complex (BLM–Topo IIIα–RMI1–RMI2) and PrimPol (DNA primase and DNA polymerase) directly associate with RPA70N (<xref ref-type="bibr" rid="bib22">Dornreiter et al., 1992</xref>; <xref ref-type="bibr" rid="bib34">Guilliam et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>; <xref ref-type="bibr" rid="bib78">Wan et al., 2013</xref>; <xref ref-type="bibr" rid="bib87">Xue et al., 2013</xref>).</p><p>In general, most of the proteins that interact with RPA70N utilize a motif of around 20 amino acids long that contains a mixture of acidic and hydrophobic residues (<xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>). The exact sequence of these motifs doesn’t share much homology, despite the similarity in the overall composition, indicating that each motif might bind to RPA70N differently (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). To better understand the mechanism of RPA70N-mediated target protein recruitment, we set out to determine the complex structures of RPA70N with the peptide motifs that bind to it. To date, quite a few studies have employed NMR chemical shifts to probe the interaction sites of RPA70N with partner proteins (<xref ref-type="bibr" rid="bib35">Guler et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">Kang et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Liu et al., 2011</xref>; <xref ref-type="bibr" rid="bib60">Ning et al., 2015</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2008b</xref>; <xref ref-type="bibr" rid="bib90">Yeom et al., 2019</xref>). The NMR chemical shift information is useful in identifying potential residues that are involved in binding, but owing to the transient nature of the interactions, the complex structures were not resolved by NMR. Several crystal structures of RPA70N in complex with bound peptide have been reported, namely those of RPA70N–p53, RPA70N–DNA2, RPA70N–PrimePol and Rfa1N–Ddc2 (<xref ref-type="bibr" rid="bib8">Bochkareva et al., 2005</xref>; <xref ref-type="bibr" rid="bib19">Deshpande et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Guilliam et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Zhou et al., 2015</xref>). However, crystallization attempts often yield crystals of RPA70N itself without peptide bound, mainly owing to the weak affinity between RPA70N and the protein sequences that it recognizes (<xref ref-type="bibr" rid="bib71">Souza-Fagundes et al., 2012</xref>). To overcome this problem, we fused each target sequence to the C-terminus of RPA70N with a flexible linker. By adjusting the sequence and the linker length of the interacting peptides, we managed to crystalize and determine the structures of RPA70N in complex with HelB, BLM, RMI1, WRN, ATRIP, MRE11, RAD9, and ETAA1 (<xref ref-type="fig" rid="fig1">Figure 1F–N</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B–K</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Structure of the RPA70N–HelB peptide complex</title><p>HelB is a conserved helicase that is involved in DNA replication initiation, in replication stress responses and in negatively regulating DNA end-resection (<xref ref-type="bibr" rid="bib35">Guler et al., 2012</xref>; <xref ref-type="bibr" rid="bib38">Hazeslip et al., 2020</xref>; <xref ref-type="bibr" rid="bib75">Taneja et al., 2002</xref>; <xref ref-type="bibr" rid="bib77">Tkáč et al., 2016</xref>). It has an RPA-binding motif located in the helicase domain and its recruitment to chromatin correlates with the level of RPA (<xref ref-type="bibr" rid="bib35">Guler et al., 2012</xref>). A recent in vitro study showed that all ssDNA-dependent activities of HelB are greatly stimulated by RPA–ssDNA filaments (<xref ref-type="bibr" rid="bib41">Hormeno et al., 2022</xref>). We crystallized a human HelB helicase peptide (HelBp1, residues 496–519) with the human RPA70N (residues 1–120) using the fusion strategy in space group P41212 and found that there is one molecule in the asymmetry unit (<xref ref-type="fig" rid="fig1">Figures 1F</xref> and <xref ref-type="fig" rid="fig2">2B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Crystal packing analysis shows that the HelB peptide from one fusion protein is bound by a neighboring RPA70N molecule (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). The electron density of the fusion linker is not observed as it is highly flexible. In the 1.6 Å structure, residues 496–517 of HelB form a four-turn α helix followed by a β turn and a 3<sub>10</sub> helix (<xref ref-type="fig" rid="fig1">Figures 1F</xref> and <xref ref-type="fig" rid="fig2">2B</xref>). The curved β sheet of RPA70 and the extending L12, L45 loops form a shallow groove where the amphipathic helix of HelB sits (<xref ref-type="fig" rid="fig1">Figures 1F</xref> and <xref ref-type="fig" rid="fig2">2B</xref>). The negatively charged residues E496, E499 and D506 of HelB form hydrogen bonds and salt bridges with RPA70N R81, T60, Q61 and R41 (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). The hydrophobic residues V500, C504 and F507 of HelB pack against a broad hydrophobic patch formed by RPA70N I83, M97, I95, V93, L87 and M57 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The mixed basic and hydrophobic character of the RPA70N groove complements the acidic-hydrophobic nature of the HelB peptide (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). The interacting residues correlate well with the results of the previous NMR chemical shift analysis and mutation studies regarding the charged and hydrophobic residues (<xref ref-type="bibr" rid="bib35">Guler et al., 2012</xref>). On the left side of the groove, W517 of HelB fits into a well-defined pocket (side-pocket) formed by the aliphatic portions of RPA70N N29, R31, R43 and S54 (<xref ref-type="fig" rid="fig1">Figures 1C</xref>, <xref ref-type="fig" rid="fig2">2D and E</xref>). HelB residues D510, E516 and T519 were stabilized by hydrogen bonding or electrostatic interactions with the side chains of RPA70N R31, N29 and R91. In addition, RPA70N R43 forms a hydrogen bond with the main chain carbonyl group of HelB W517, further stabilizing the folded-back conformation of the HelB peptide (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The overall binding mode of HelB to RPA70N is similar to that of DNA2 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). The amphipathic helix of HelB overlaps with the DNA2 helix while the β turn coincides with the β turn region of DNA2. Both peptides have a conserved hydrophobic residue that fits into the side pocket (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). ITC titration results showed that mutation of W517 in HelB to alanine reduced the affinity between HelB peptide and RPA70N from around 4 μM to 16 μM (<xref ref-type="fig" rid="fig2">Figure 2G</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B–1D</xref>), highlighting the contribution of side-pocket interactions to the overall binding strength. Further mutation of the hydrophobic residues F507 and C504 in HelB reduced the affinity between RPA70N and HelB by ten fold (37 μM). In HeLa cells, these mutations led to reduced colocalization of HelB–EGFP and endogenous RPA in untreated cells ls and in camptothecin (CPT) or hydroxyurea (HU) treated cells to different degrees (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E and F</xref>). HelB-EGFP with C504A/F507A/W517A triple mutation almost completely lost the ability to form obvious RPA foci (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E and F</xref>). Coimmunoprecipitation (co-IP) analysis also showed that triple mutant HelB-EGFP pulled down much less RPA than WT (<xref ref-type="fig" rid="fig2">Figure 2K</xref>). In addition, ITC titration showed that mutation of the conserved arginine esidues in RPA70N (R31, R41, R43, R91) significantly reduced the binding of RPA70N to  HelBp1 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G–J</xref>). Together, these results revealed the molecular basis  for the HelB-RPA70N interaction.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Structure of the RPA70N–HelB complex.</title><p>(<bold>A</bold>) Linear domain diagram of HelB showing the position and sequence of the RPA70N interacting motif. SLD: subcellular domain. (<bold>B</bold>) Structure of RPA70N in complex with HelB, showing the surface charges of RPA70N; hydrophobic and negatively charged residues of HelB are displayed as sticks, the HelB peptide is colored in cyan. (<bold>C</bold>) Close-up view of the amphipathic HelB helix interacting with the groove of RPA70N. HelB peptide is colored in cyan and RPA70N in beige. Green dashed lines indicate hydrogen bonds or salt bridges. (<bold>D</bold>) Side view of the RPA70N–HelB structure, the electrostatic surface of RPA70N is displayed and the side pocket is highlighted. The representation is rotated 90° compared to (<bold>B</bold>). (<bold>E</bold>) Close-up view of the side-pocket residues coordinating the C-terminal part of the HelB peptide. Green dashed lines indicate hydrogen bonds or salt bridges. (<bold>F</bold>) Superposition of RPA70N–HelB structure with the RPA70N–DNA2 structure (PDB:5EAY). HelB is colored in cyan, DNA2 in light-magenta. The direction of the HelB and DNA2 peptides in the RPA70N groove is the same in both structures. Both proteins have a hydrophobic residue inserted into the side pocket of RPA70N. (<bold>G</bold>) Isothermal titration calorimetry (ITC) results for WT HelB (496–519aa), W517A or C504A/F507A/W517A mutant peptides with RPA70N. (<bold>H</bold>) HeLa cells expressing HelB–EGFP, HelB (W517A)–EGFP, HelB (C504A/W517A)–EGFP, or HelB (C504A/F507A/W517A)–EGFP were treated with medium control (NT) or camptothecin (CPT) (2 μM, 2 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10 μm. (<bold>I</bold>) and (<bold>J</bold>). Quantification of data from (<bold>H</bold>). Data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, and cells containing more than three bright HelB and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>K</bold>) Immunoprecipitation and western blot showing that mutation of HelB residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Raw data of all western blots from <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Characterization of RPA70N–HelB interaction (related to <xref ref-type="fig" rid="fig2">Figure 2</xref>).</title><p>(<bold>A</bold>) Crystal packing analysis indicates that a HelB peptide from one RPA70N–HelB fusion molecule binds to the RPA70N portion of a neighboring molecule in the crystal. (<bold>B–D</bold>) ITC titration profiles of (<bold>B</bold>) WT HelB (496–519aa) peptide, (<bold>C</bold>) W517A mutant peptide or (<bold>D</bold>) C504A/F507A/W517A mutant peptide with RPA70N. (<bold>E</bold>) HeLa cells expressing HelB–EGFP, HelB (W517A)–EGFP, HelB (C504A/W517A)–EGFP or HelB (C504A/F507A/W517A)–EGFP were treated with hydroxyurea (HU) (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10 μm. (<bold>F</bold>) Quantification of data from (<bold>E</bold>). Data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, cells containing more than three bright HelB and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>G</bold>) ITC titration results for WT RPA70N(1–120aa), R31H, R91A or R41A/R43A/R91A mutant protein with HelB peptide. R31H was found in some cancer samples. (<bold>H–J</bold>) ITC titration profiles of (<bold>H</bold>) R31H mutant protein, (<bold>I</bold>) R91A mutant protein or (<bold>J</bold>) R41A/R43A/R91A mutant protein with HelB peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Structures of the RPA70N–BLM peptide complexes</title><p>BLM helicase is a multifunctional RecQ family helicase. It is involved in DNA-end resection, restart of stalled replication forks, dissolving Holliday junctions, and processing of ultra-fine DNA bridges (<xref ref-type="bibr" rid="bib11">Bythell-Douglas and Deans, 2021</xref>; <xref ref-type="bibr" rid="bib16">Chu and Hickson, 2009</xref>; <xref ref-type="bibr" rid="bib18">Croteau et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Kitano, 2014</xref>; <xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>). It has two RPA70N binding motifs in the N-terminal disordered region, namely residues 146–165 (BLMp1) and residues 550–570 (BLMp2) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="bibr" rid="bib20">Doherty et al., 2005</xref>; <xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>). Shorrocks and coworkers reported that RPA and BLM proteins accumulated along laser lines within 5 min but at relatively low levels, RPA microfoci appeared in ~50% of irradiated cells after 15 min as a result of DNA end-resection in S and G2 cells. Shortly afterwards, at 20 min, BLM microfoci appeared and co-localized with RPA; whereas a BLM mutant lacking both BLMp1 and BLMp2 failed to form microfoci (<xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>). We fused BLMp1 and BLMp2 separately to RPA70N and determined the structures of these regions (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Structures of two RPA70N–BLM complexes.</title><p>(<bold>A</bold>) Linear domain diagram of BLM showing the position and sequence of RPA70N interacting motifs. DHBN, dimerization helical bundle in N-terminal region; RDC, RecQ-conserved domain; HRDC, helicase and RNaseD in C-terminal region. (<bold>B</bold>) Ribbon representation of the RPA70N–BLMp2 crystal structure, the BLMp2 peptide is coordinated by two RPA70N molecules. BLMp2 is colored in magenta and the two RPA70N molecules are colored in brown and light-blue, respectively. (<bold>C</bold>) Close-up view of BLMp2 interacting with the RPA70Na groove. Interacting residues are shown as sticks, green dashed lines indicate hydrogen bonds or salt bridges. (<bold>D</bold>) Close-up view of BLMp2 interacting with RPA70Nb α1, interacting residues are shown as sticks, green dashes indicate hydrogen bonds or salt bridges. (<bold>E</bold>) ITC titration results for WT BLMp2 (550–570aa), F561A or D560A/F561A/D562A mutant peptide with RPA70N. (<bold>F</bold>) Ribbon representation of the RPA70N–BLMp1 crystal structure: the BLMp1 peptide is coordinated by two RPA70N molecules. BLMp1<bold><sup>a</sup></bold> is colored in purple, BLMp1<bold><sup>b</sup></bold> is colored in pink and the two RPA70N molecules are colored in yellow and light-green, respectively. (<bold>G</bold>) Close-up view of BLMp1 interacting with the RPA70Na groove. Interacting residues are shown as sticks, green dashes indicate hydrogen bonds or salt bridges. (<bold>H</bold>) Close-up view of BLMp1 interacting with the RPA70Nb side-pocket. Interacting residues are shown as sticks, green dashes indicate hydrogen bonds or salt bridges. (<bold>I</bold>) ITC titration results for WT BLMp1 (146–165aa), F160A or W154A/F160A mutant peptide with RPA70N. (<bold>J, K</bold>) HeLa cells expressing EGFP–BLM, EGFP–BLM(W154A/F160A, p1M), EGFP–BLM (D560A/F561A/D562A, p2M), or EGFP–BLM(W154A/F160A/D560A/F561A/D562A, p1p2M) were treated with medium control (NT) or CPT (2 μM, 2 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. (<bold>L, M</bold>). Quantification of data from (<bold>J</bold>) and (<bold>K</bold>). Data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, cells containing more than three bright BLM and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>N</bold>) Immunoprecipitation and western blot showing that mutation of BLM residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Raw data from all western blots shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Characterization of RPA70N–BLM interaction (related to <xref ref-type="fig" rid="fig3">Figure 3</xref>).</title><p>(<bold>A</bold>) Surface representation of the two RPA70N molecules interacting with a BLMp2 peptide, which is displayed as magenta sticks. (<bold>B–D</bold>) ITC titration profiles of (<bold>B</bold>) WT BLMp2 (550–570 aa) peptide, (<bold>C</bold>) F561A mutant peptide or (<bold>D</bold>) D560A/F561A/D562A mutant peptide with RPA70N. (<bold>E–G</bold>) ITC titration profiles of (<bold>E</bold>) WT BLMp1 (146–165aa) peptide, (<bold>F</bold>) F160A mutant peptide or (<bold>G</bold>) W154A/F160A mutant peptide with RPA70N. (<bold>H</bold>) Like BLMp1, p53 (orange) also binds two RPA70N molecules with M44A inserts into the side pocket of a neighboring RPA70N (as shown in PDB 2B3G). (<bold>I, J</bold>) Superposition of the RPA70N–BLMp1 structure with that of RPA70N–p53 (2B3G), showing the different positions of p53 M44 and BLM F160. In addition, the two peptides are positioned in different directions.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Characterization of the RPA70N–BLM interaction (related to <xref ref-type="fig" rid="fig3">Figure 3</xref>).</title><p>(<bold>A</bold>) HeLa cells expressing EGFP–BLM, EGFP–BLM (W154A/F160A, p1M), EGFP–BLM (D560A/F561A/D562A, p2M) or EGFP–BLM (W154A/F160A/D560A/F561A/D562A, p1p2M) were treated with HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. (<bold>B</bold>) Quantification of data from (<bold>A</bold>) and (<bold>B</bold>). Data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, and cells containing more than three bright BLM and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>C</bold>) ITC titration results for WT RPA70N (1–120aa), R91A or R41A/R43A/R91A mutant protein with BLMp2 peptide. (<bold>D–E</bold>) ITC titration profiles of (<bold>D</bold>) R91A mutant protein or (<bold>E</bold>) R41A/R43A/R91A mutant protein with BLMp2 peptide. (<bold>F</bold>) ITC titration results for WT RPA70N (1–120aa), R31H, R91A or R41A/R43A/R91A mutant protein with BLMp1 peptide. (<bold>G–I</bold>) ITC titration profiles of (<bold>G</bold>) R31H mutant protein, (<bold>H</bold>) R91A mutant protein and (<bold>I</bold>) R41A/R43A/R91A mutant protein with BLMp1 peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig3-figsupp2-v1.tif"/></fig></fig-group><p>In the structure of RPA70N–BLMp2, BLM residues 550–564 are visible and the peptide is bound by two RPA70N molecules (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). The C-terminal part of the kinked BLM peptide fits onto the RPA70N groove, with F556, I558 and F561 making contacts with the hydrophobic patch of RPA70N, while RPA70N residues R41, K88, R91 and R43 form salt bridges or hydrogen bonds with BLM D560, D552, D562 and the main chain carbonyl group of F561 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Interestingly, the N-terminal half of BLMp2 latches onto the α1 region of a nearby RPA70N<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). K16<bold><sup>b</sup></bold> from RPA70N<bold><sup>b</sup></bold> forms several ionic interactions with BLM D554, D557 and D559 to neutralize the negative charges. Q15<bold><sup>b</sup></bold> also contributes to the interaction by forming two hydrogen bonds with BLM D557. Near the tip of the BLMp2 peptide, Y551 fits onto a small hydrophobic surface formed by A9<bold><sup>b</sup></bold>, A12<bold><sup>b</sup></bold>, I13<bold><sup>b</sup></bold> and I21<bold><sup>b</sup></bold> in RPA70N<bold><sup>b</sup></bold>, its main chain amide group also forms a hydrogen bond with the carbonyl group of E7<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Overall, it appears that BLMp2 promotes Loop 12 of one RPA70N dimer to interact with α1<bold><sup>b</sup></bold> of the other RPA70N, and that each RPA70N provides some of the binding surface for BLMp2 (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Using ITC, we found that BLMp2 binds to RPA70N with a relatively weak <italic>K<sub>D</sub></italic> of around 18 μM, and that mutation of BLMp2 residues (D560A, F561A, D562A) almost abolished the binding between BLMp2 and RPA70N (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B-D</xref>).</p><p>In the structure of RPA70N–BLMp1, BLMp1 also adopts a kinked conformation and bridges two RPA70N molecules (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). However, one major difference is that BLMp1 binds to RPA70N in the reverse direction when compared to BLMp2, HelB or DNA2 (<xref ref-type="fig" rid="fig1">Figure 1F–H</xref>). The N-terminal part of BLMp1 forms a one-turn helix followed by a γ turn (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). BLM W154 inserts into a hydrophobic pocket formed by RPA70N V93, I95, M57, I33 and the aliphatic part of R43, and stacks with M57. BLM L148 stacks on top of W154, and BLM I151 packs onto the side chains of RPA70N I33, M57 and R41 (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). At the middle of the BLMp1 peptide, D156 interacts with RPA70N K88 and the peptide forms another β turn. The C-terminal part of BLMp1 adopts an extended conformation, with F160 anchored in the side pocket of a nearby RPA70N<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). The RPA70N<bold><sup>b</sup></bold> residues R43<bold><sup>b</sup></bold>, R31<bold><sup>b</sup></bold> also interact with the BLM D158 side chain and with main chain oxygen atoms of D159 and M157. The <italic>K<sub>D</sub></italic> of the BLMp1–RPA70N complex, as determined by ITC, is around 16.7 μM, similar to that of the corresponding BLMp2 complex (<xref ref-type="fig" rid="fig3">Figure 3I</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Mutation of BLM F160 to alanine greatly reduced the affinity between BLMp1 and RPA70N, resulting in a <italic>K<sub>D</sub></italic> of around 85 μM. F160A and W154A double mutation reduced the affinity even more (<xref ref-type="fig" rid="fig3">Figure 3I</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F and G</xref>). The two RPA70N molecules are connected by the BLMp1 peptide but do not make other contacts (<xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>). The way that BLMp1 bridges two RPA70N molecules is analogous to the role of the p53 peptide (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1I and J</xref>). However, the direction of the BLMp1 peptide in the groove is reversed compared to that of the p53 peptide (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>).</p><p>In untreated HeLa cells, WT or mutant EGFP–BLM formed few foci (<xref ref-type="fig" rid="fig3">Figure 3J</xref>). CPT treatment increased the percentage of cells with obvious foci to around 50% for WT and 40% for BLMp1 or BLMp2 mutants (<xref ref-type="fig" rid="fig3">Figure 3K</xref>). However, the BLMp1 or BLMp2 mutants generally displayed fewer foci per cell when compared to WT (<xref ref-type="fig" rid="fig3">Figure 3J–M</xref>). The BLMp1 and BLMp2 dual mutant formed far fewer foci, even after CPT treatment (<xref ref-type="fig" rid="fig3">Figure 3J–M</xref>). Similar phenomena were observed for HU-treated cells (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A and B</xref>). Co-IP experiments showed that mutating the RPA70N interacting residues in BLM reduced its binding to RPA (<xref ref-type="fig" rid="fig3">Figure 3N</xref>). These results are in agreement with the results of Shorrocks, who reported that BLM has two RPA70N interacting motifs (<xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>). Not surprisingly, mutation of the conserved arginine residues in RPA70N (R31, R41, R43, R91) significantly reduced the binding of RPA70N to BLMp2 and BLMp1 (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C–I</xref>).</p></sec><sec id="s2-3"><title>Structure of the RPA70N–RMI1 peptide complex</title><p>RMI1 is another RPA partner. It is a subunit in the BTR complex and mainly mediates protein–protein interaction (<xref ref-type="bibr" rid="bib69">Shorrocks et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib84">Xu et al., 2008a</xref>; <xref ref-type="bibr" rid="bib87">Xue et al., 2013</xref>). The RPA70N interaction motif is located between its two OB folds (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In the RPA70N–RMI1 complex structure, RMI1 residues 243-259 form two short α helixes with a β turn in the middle (<xref ref-type="fig" rid="fig4">Figures 4B</xref> and <xref ref-type="fig" rid="fig1">1I</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). The overall arrangement is similar to the complex of RPA70N–BLMp1 with the N-terminal helix in the groove and the C-terminal helix binding to a neighboring RPA70N<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig4">Figures 4B</xref> and <xref ref-type="fig" rid="fig3">3F</xref>). RMI1 L247 of the N-terminal helix fits into a hydrophobic pocket at the bottom of the RPA70N groove (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). RMI1 L248 and L251 interact with the hydrophobic side chains of RPA70N I33, M57 and the aliphatic part of R41. RMI1 D244 and E246 are stabilized by electrostatic interactions with RPA70N R31, R43 and R91. The folded-back C-terminal helix also interacts with RPA70N K88 by forming several hydrogen bonds (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). RMI1 N254 inserts into the side pocket of a neighboring RPA70N<bold><sup>b</sup></bold> and forms a few hydrogen bonds with N29<bold><sup>b</sup></bold> and R31<bold><sup>b</sup></bold> side chains (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). D252 also interacts with S54<bold><sup>b</sup></bold> and R43<bold><sup>b</sup></bold>, further strengthening the interaction (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Analogous to RPA70N–BLMp1, the two RPA70N molecules coordinating the RMI1 peptide aren’t making any contact (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Superposition of the two structures showed that BLMp1 F160 and RMI1 N254 point in the same direction but not at the exact same location, indicating that the second RPA70N molecule is able to adjust to different peptide sequences for binding (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). ITC titration showed that the RMI1 peptide binds to RPA70N with a <italic>K<sub>D</sub></italic> of around 14.5 μM, mutation of N254 reduced the affinity between RMI1 and RPA70N to around 25.6 μM (<xref ref-type="fig" rid="fig4">Figure 4F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>). In HeLa cells, the expression of WT or N254A EGFP–RMI1 resulted in very few foci. Nevertheless, N254A mutation led to less RPA-RMI1 colocalization as measured by fluorescent intensity analysis across the nucleus (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Accordingly, co-IP results showed reduced RPA interaction for the RMI1 N254A mutant (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Mutation of the conserved arginine residues in RPA70N (R31, R41, R43, R91) significantly reduced the binding of RPA70N to RMI1 (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D–H</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Structure of the RPA70N–RMI1 complex.</title><p>(<bold>A</bold>) Linear domain diagram of RMI1, showing the position and sequence of the RPA70N interacting motif. (<bold>B</bold>) Ribbon representation of the RPA70N–RMI1 crystal structure, the RMI1 peptide is coordinated by two RPA70N molecules. RMI1 is colored in olive and the two RPA70N molecules are colored pale-cyan and light-pink. The other RMI1 peptide in RPA70Nb is colored green. (<bold>C</bold>) Close-up view of RMI1 interacting with the RPA70Na groove, interacting residues are shown as sticks, green dashed lines indicate hydrogen bonds or salt bridges. (<bold>D</bold>) Close-up view of RMI1 interacting with the RPA70Nb side-pocket. Interacting residues are shown as sticks, and green dashed lines indicate hydrogen bonds or salt bridges. (<bold>E</bold>) Superposition of the RPA70N–RMI1 structure with that of the RPA70N–BLMp1 complex: RMI1 and BLMp1 interact with RPA70N in a similar manner. (<bold>F</bold>) ITC titration results for the WT RMI1 peptide (243–262aa) or the N254A mutant peptide with RPA70N. (<bold>G</bold>) HeLa cells expressing EGFP–RMI1 or EGFP–RMI1(N254A) were treated with medium control, CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. The intensities of the fluorescent signals for EGFP–RMI1 or EGFP RMI1(N254A) and RPA32 are displayed on the right. (<bold>H</bold>) Immunoprecipitation and western blotting showed that mutation of RMI1 residues reduced the RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitation, which was followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Raw data for all all western blots shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Characterization of the RPA70N–RMI1 interaction (related to <xref ref-type="fig" rid="fig4">Figure 4</xref>).</title><p>(<bold>A</bold>) Surface representation of the two RPA70N molecules interacting with an RMI1 peptide, which is displayed as olive-colored sticks. (<bold>B–C</bold>) ITC titration profiles of WT RMI1 (243–262aa) peptide (<bold>B</bold>) and N254A mutant peptid (<bold>C</bold>) with RPA70N. (<bold>D–E</bold>) ITC titration results for WT RPA70N (1–120aa), R31H, R91A or R41A/R43A/R91A mutant protein with RMI1 peptide. (<bold>F–H</bold>) ITC titration profiles of R91A mutant protein (<bold>F</bold>), R41A/R43A/R91A mutant protein (<bold>G</bold>) or R31H mutant protein (<bold>H</bold>) with RMI1 peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig4-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Structure of the RPA70N–WRN peptide complex</title><p>WRN nuclease-helicase belongs to the RecQ family of DNA helicases and plays important roles in DNA repair and in the maintenance of genome integrity (<xref ref-type="bibr" rid="bib16">Chu and Hickson, 2009</xref>; <xref ref-type="bibr" rid="bib18">Croteau et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Kitano, 2014</xref>; <xref ref-type="bibr" rid="bib56">Mukherjee et al., 2018</xref>). Studies carried out by <xref ref-type="bibr" rid="bib20">Doherty et al., 2005</xref> and <xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref> showed that RPA stimulates WRN helicase activity in a concentration-dependent manner and that the helicase activity of WRN requires the binding of multiple RPAs (<xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>). WRN has two tandem RPA-binding motifs with the same sequence localized between its nuclease and helicase domains (<xref ref-type="bibr" rid="bib20">Doherty et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Shen et al., 2003</xref>; <xref ref-type="bibr" rid="bib90">Yeom et al., 2019</xref>; <xref ref-type="fig" rid="fig5">Figure 5A</xref>). We fused one WRN motif to RPA70N, and the fusion construct crystallized in space group P212121 with two molecules in the asymmetry unit (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). In the structure, WRN 435–451 form a continuous α helix and insert into the amphipathic groove of a symmetry-related RPA70N<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Residues E439-R31<bold><sup>b</sup></bold>-D443-R43<bold><sup>b</sup></bold>-E442-R91<bold><sup>b</sup></bold>-E445 form a series of electrostatic interactions, and WRN M446 and L449 contact the hydrophobic patch formed by RPA70N<bold><sup>b</sup></bold> L87<sup><bold>b</bold></sup>, V97<bold><sup>b</sup></bold>, I33<bold><sup>b</sup></bold>, M57<bold><sup>b</sup></bold> and I95<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The N-terminal part of each WRN peptide helix interacts with the RPA70N peptide that it fused to. WRN<bold><sup>b</sup></bold> Y436<bold><sup>b</sup></bold> fits into the side-pocket and forms two hydrogen bonds with RPA70N<bold><sup>b</sup></bold> R31<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Compared to the RPA70N–p53 structure, the direction of the WRN<bold><sup>a</sup></bold> peptide in the groove is reversed and the positions of WRN Y436 and p53 M44 are different (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). The direction of the other WRN<bold><sup>b</sup></bold> peptide bound to the side pocket is the same as that of p53<bold><sup>b</sup></bold> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A and B</xref>). ITC titration of the WRN peptide with RPA70N yielded a <italic>K<sub>D</sub></italic> value around 11.6 μM, whereas M466A mutation increased the <italic>K<sub>D</sub></italic> value to around 37.4 μM (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C and D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Structure of the RPA70N–WRN complex.</title><p>(<bold>A</bold>) Linear domain diagram of WRN showing the position and sequence of RPA70N-interacting motifs. (<bold>B</bold>) Ribbon representation of the RPA70N–WRN crystal structure. The fused WRN peptide forms an α helix and inserts into the groove of the symmetry-related RPA70N molecule. The two RPA70N molecules and linked WRN peptides are colored in purple-blue and light-green, respectively. (<bold>C</bold>) Close-up view of WRN<bold><sup>a</sup></bold> interacting with the RPA70N<bold><sup>b</sup></bold> groove, interacting residues are shown as sticks, green dashed lines indicate hydrogen bonds or salt bridges. (<bold>D</bold>) Close-up view of WRN<bold><sup>b</sup></bold> interacting with the RPA70N<bold><sup>b</sup></bold> side-pocket. Interacting residues are shown as sticks, whereas green dashed lines indicate hydrogen bonds or salt bridges. (<bold>E</bold>) Y436<bold><sup>b</sup></bold> from WRN<bold><sup>b</sup></bold> inserts into the side pocket of RPA70N<bold><sup>b</sup></bold> while WRN<bold><sup>a</sup></bold> sits in the basic groove of RPA70N<bold><sup>b</sup></bold>. (<bold>F</bold>) ITC titration data for the WT WRN peptide (435–451aa) with RPA70N: the titration appears to be endothermic. (<bold>G</bold>) ITC titration data for the M466A mutant WRN peptide (435–451aa) with RPA70N. (<bold>H</bold>) HeLa cells expressing WRN–EGFP or WRN (M446A/M473A)–EGFP were treated with medium control (NT), CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. (<bold>I, J and K</bold>) Quantification of data from (<bold>H</bold>), data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed. Cells containing more than three bright WRN and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>L</bold>) Immunoprecipitation and western blot showing that the mutation of WRN residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitation, which was followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Raw data for all of the western blots shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Characterization of the RPA70N–WRN interaction (related to <xref ref-type="fig" rid="fig5">Figure 5</xref>).</title><p>(<bold>A</bold>) Ribbon representation of the two WRN peptides interacting with RPA70N. WRN<bold><sup>a</sup></bold> (purple-blue) binds to the groove, while WRN<bold><sup>b</sup></bold> (light green) binds to the side pocket with Y436<bold><sup>b</sup></bold>.(<bold>B</bold>) Ribbon representation of two p53 peptides binding to one RPA70N molecule (PDB:2B3G). p53<bold><sup>a</sup></bold> (orange) binds to the groove, while p53<bold><sup>b</sup></bold> (yellow) binds to the side pocket with M44<bold><sup>b</sup></bold>. The direction of the p53<bold><sup>a</sup></bold> peptide is reversed compared to that of WRN<bold><sup>a</sup></bold>, and as a result, Y436<bold><sup>a</sup></bold> is at a different location when compared to M44<bold><sup>a</sup></bold>.(<bold>C–D</bold>.) ITC titration profiles of the WT WRN (435–451aa) peptide (<bold>C</bold>) and the M446A mutant peptide (<bold>D</bold>) with RPA70N. (<bold>E–F</bold>) ITC titration data for WT RPA70N (1–120aa), R31H, R91A or R41A/R43A/R91A mutant proteins with the WRN peptide. (<bold>G–I</bold>) ITC titration profiles of R91A mutant protein (<bold>G</bold>), R41A/R43A/R91A mutant protein (<bold>H</bold>) or R31H mutant protein (<bold>I</bold>) with the WRN peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig5-figsupp1-v1.tif"/></fig></fig-group><p>In HeLa cells, M466A and M473A double mutants had reduced WRN–RPA colocalization, as well as a reduced percentage of cells with obvious RPA foci (<xref ref-type="fig" rid="fig5">Figure 5H–K</xref>). EGFP–WRN with M466A and M473A double mutation also pulled down less RPA. Mutation of the conserved arginine residues in RPA70N (R31, R41, R43, R91) greatly reduced the binding of RPA70N to the WRN peptide (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E–1I</xref>). These data jointly demonstrate that RPA70N-mediated interaction with WRN is critical for WRN recruitment during the DNA damage response.</p></sec><sec id="s2-5"><title>Structure of the RPA70N–ATRIP peptide complex</title><p>ATR is a member of the PIKK kinase family, and the ATR–ATRIP complex is a key regulator of the DNA damage checkpoint. The complex is recruited to DNA damage sites by RPA coated ssDNA through ATRIP (<xref ref-type="bibr" rid="bib3">Ball et al., 2005</xref>; <xref ref-type="bibr" rid="bib93">Zou and Elledge, 2003</xref>). We crystallized the RPA70N–ATRIP fusion protein in the P212121 space group with one molecule in the asymmetric unit (<xref ref-type="fig" rid="fig1">Figure 1K</xref>, <xref ref-type="fig" rid="fig6">Figure 6A and B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). ATRIP peptide binds to the RPA70N it fused to and the linker region is disordered. In the structure, ATRIP residues 53–69 form a three-turn helix with two short flanking loops (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). The hydrophobic side of the ATRIP helix, consisting of F55, L60, L63 and L66, packs against the broad hydrophobic patch of the RPA70N groove (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). RPA70N R43 and R91 form salt-bridges and hydrogen bonds with ATRIP D54 and main-chain carbonyl groups at the N-terminus of the ATRIP peptide. At the C-terminus of the peptide, RPA70N R41 forms a hydrogen bond with the carbonyl group of ATRIP L63 while ATRIP E62 forms a hydrogen bond with the main-chain amide group of RPA70N K88. The direction of the ATRIP peptide is inverted compared to HelB or DNA2, instead it is the same as that seen in the <italic>Kluyveromyces lactis</italic> Ddc2 (ATRIP)–Rfa1N complex (PDB: 5OMB) (<xref ref-type="bibr" rid="bib19">Deshpande et al., 2017</xref>), with both Ddc2 and ATRIP using a hydrophobic residue (F55 in ATRIP or I14 in Ddc2) at the N-terminus to anchor the peptide at the groove (<xref ref-type="fig" rid="fig6">Figures 6C</xref>, <xref ref-type="fig" rid="fig1">1F and K</xref>). Aiming to inhibit the ATRIP–RPA70N interaction in cells and based on the structure of the RPA70N–p53 complex, <xref ref-type="bibr" rid="bib31">Frank et al., 2014</xref> engineered a stapled helix peptide that binds to RPA70N and determined the co-crystal structure of the synthetic helix with RPA70N. In their structure (PDB:4NB3), the peptide is in a reversed orientation when compared to our structure or the Ddc2–Rfa1N structure and employs a 3,4-dichloro-substituted phenylalanine (ZCL) to bind the hydrophobic pocket that is bound by F55 in ATRIP (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Mutation of F55 to alanine greatly reduced the affinity of ATRIP towards RPA70N, indicating that the hydrophobic interactions mediated by F55 are critical for maintaining ATRIP–RPA70N association (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). F55A/L60A/L63A triple mutation almost abolished binding between the ATRIP peptide and RPA70N (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). In HeLa cells, WT ATRIP and RPA colocalized very well (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). The ATRIP F55A single mutant displayed slightly weakened colocalization, whereas the F55A/L60A/L63A triple mutant showed worse colocalization (<xref ref-type="fig" rid="fig6">Figure 6F–J</xref>). Similarly, F55A and F55A/L60A/L63A pulled down less RPA than WT in co-IP experiments (<xref ref-type="fig" rid="fig6">Figure 6K</xref>). Mutation of the conserved arginine residues in RPA70N (R41, R43, R91) significantly reduced the binding of RPA70N to ATRIP (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D–1F</xref>). Our results provided the structural basis for RPA70N-mediated ATRIP/ATR recruitment, which is a crucial response to DNA damage.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Structure of the RPA70N–ATRIP complex.</title><p>(<bold>A</bold>) Linear domain diagram of ATRIP, showing the position and sequence of the RPA70N-interacting motif. CC, coiled-coiled domain; ATR-BD, ATR binding domain. (<bold>B</bold>) Ribbon representation of the RPA70N–ATRIP crystal structure. The ATRIP peptide is colored in violet and RPA70N in light grey. Important interacting residues are shown as sticks, and green dashed lines indicate hydrogen bonds or salt bridges. (<bold>C</bold>) Alignment of the RPA70N–ATRIP structure with the Ddc2–Rfa1N structure (PDB: 5OMB), showing that ATRIP and Ddc2 bind to RPA70N in the same direction. RPA70N–ATRIP components are colored as in (<bold>B</bold>), Ddc2 is colored in green and Rfa1N is colored in blue. (<bold>D</bold>) Superposition of the RPA70N–ATRIP structure with that of the RPA70N-stapled peptide complex (PDB:4NB3). For 4NB3, RPA70N is colored in light-green and the stapled peptide is colored in marine. ZCL is 3,4-dichloro-substituted phenylalanine. The direction of the stapled peptide is reversed when compared to that of ATRIP. (<bold>E</bold>) ITC titration data for WT ATRIP (53–69 aa) and for F55A or F55A/L60A/L63A mutant peptides with RPA70N. (<bold>F, G</bold>) HeLa cells expressing ATRIP–EGFP, ATRIP (F55A)–EGFP, or ATRIP (F55A/L60A/L63A)–EGFP were treated with medium control (NT), CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. The intensities of the fluorescent signals for ATRIP–EGFP, ATRIP (F55A)–EGFP or ATRIP (F55A/L60A/L63A)–EGFP and RPA32 are displayed on the right. (<bold>H, I and J</bold>) Quantification of data from (<bold>F</bold>) and (<bold>G</bold>), data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, and cells containing more than three bright ATRIP and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>K</bold>) Immunoprecipitation and western blots showed that mutation of ATRIP residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, which were followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Raw data for all of the western blots shown in <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Characterization of the RPA70N–ATRIP interaction (related to <xref ref-type="fig" rid="fig6">Figure 6</xref>).</title><p>(<bold>A–C</bold>) ITC titration profiles of WT ATRIP peptide (53–69aa) (<bold>A</bold>), F55A mutant peptide (<bold>B</bold>) or F55A/L60A/L63A mutant peptide (<bold>C</bold>) with RPA70N. (<bold>D</bold>) ITC titration data for WT RPA70N (1–120aa), R91A or R41A/R43A/R91A mutant proteins with ATRIP peptide. (<bold>E–F</bold>) ITC titration profiles of the R41A/R43A/R91A mutant protein (<bold>E</bold>) and the PA70N R91A mutant protein (<bold>F</bold>) with ATRIP peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Structure of the RPA70N–MRE11 peptide complex</title><p>The MRN complex, which consists of MRE11–RAD50–NBS1 in a 2:2:1 ratio, is a central hub of DNA double-strand break repair pathways (<xref ref-type="bibr" rid="bib65">Rotheneder et al., 2023</xref>; <xref ref-type="bibr" rid="bib74">Syed and Tainer, 2018</xref>). The MRE11 subunit has nuclease activities that are required for DNA end processing. Several studies have demonstrated that MRE11 physically associates with RPA70N through a motif in the C-terminal region, and that this interaction is required for the correct localization of MRN to replication centers and for the S-phase checkpoint (<xref ref-type="bibr" rid="bib61">Oakley et al., 2009</xref>; <xref ref-type="bibr" rid="bib62">Olson et al., 2007</xref>; <xref ref-type="bibr" rid="bib64">Robison et al., 2004</xref>). We fused the RPA interacting sequence of MRE11 to RPA70N and crystallized the fusion protein in the P212121 space group with one molecule in the asymmetric unit (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). MRE11 residues (538–563) form a long helix with a short N-terminal loop situated in the basic groove. Positively charged RPA residues R91, R43, R41, R81 and K88 interact with negatively charged D544, D549, E552, D559 and D543 from MRE11. Among these residues, D543 and D544 were previously shown to be important for RPA association (<xref ref-type="bibr" rid="bib62">Olson et al., 2007</xref>). Mutation of the conserved arginine residues in RPA70N (R41, R43, R91) significantly reduced the binding of RPA70N to MRE11 peptide (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–1C</xref>). In addition to these charge–charge interactions, hydrophobic MRE11 F540, L545, I548, A551 and A555 residues pack against the hydrophobic residues at the bottom of the RPA70N basic groove. In addition, MRE11 N556 and S547 form several hydrogen bonds with RPA70N Q61 and N85. ITC titration showed that MRE11 binds to RPA70N with a <italic>K<sub>D</sub></italic> of round 16.3 μM, whereas the triple mutation of the hydrophobic residues F540, L545 and I548 resulted in a <italic>K<sub>D</sub></italic> value that was much higher than 100 μM (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D and E</xref>). Similar to the observation by <xref ref-type="bibr" rid="bib62">Olson et al., 2007</xref> in fibroblast IMR90 cells, MRE11–FLAG colocalized with endogenous RPA in HeLa cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). MRE11–FLAG with F540/L545/I548 triple mutation led to slightly worse colocalization, in agreement with its reduced binding to RPA in coimmunoprecipitation experiments (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Structure of the RPA70N–MRE11 complex.</title><p>(<bold>A</bold>) Linear domain diagram of MRE11, showing the position and sequence of the RPA70N-interacting motif. (<bold>B</bold>) Ribbon representation of the RPA70N–MRE11 crystal structure. The MRE11 peptide is colored in brown and RPA70N in light grey. Interacting residues are shown as sticks, and green dashed lines indicate hydrogen bonds or salt bridges. (<bold>C</bold>) ITC titration data for WT MRE11 (538–563aa) or F540A/I548A/L545A mutant peptide with RPA70N. (<bold>D</bold>) HeLa cells expressing MRE11–Flag or MRE11–Flag (F540A/I548A/L545A) were treated with medium control, CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with anti-Flag and anti-RPA32 antibodies. The scale bar is 10  μm. The intensity of fluorescent signals for MRE11–Flag, MRE11–Flag (F540A/I548A/L545A) and RPA32 are displayed on the right. (<bold>E</bold>) Immunoprecipitation and western blot showed that mutation of MRE11 residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, which were followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Raw data for all of the western blots shown in <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Characterization of the RPA70N–MRE11 interaction (related to <xref ref-type="fig" rid="fig7">Figure 7</xref>).</title><p>(<bold>A</bold>) ITC titration data for WT RPA70N (1–120aa) and R91A or R41A/R43A/R91A mutant proteins with MRE11 peptide (538–563aa). (<bold>B–C</bold>) ITC titration profiles of RPA70N R91A mutant protein (<bold>B</bold>) and R41A/R43A/R91A mutant protein (<bold>C</bold>) with MRE11 peptide. (<bold>D–E</bold>) ITC titration profiles of WT MRE11 peptide (<bold>D</bold>) or MRE11 I548A/F540A/L545A mutant peptide (<bold>E</bold>) with RPA70N.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig7-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Structure of the RPA70N–RAD9 peptide complex</title><p>The RAD9–HUS1–RAD1 (9-1-1) complex is a heterotrimeric ring-shaped molecule that is loaded onto DNA at sites of DNA damage. It plays important roles in the DNA damage-induced checkpoint response (<xref ref-type="bibr" rid="bib21">Doré et al., 2009</xref>; <xref ref-type="bibr" rid="bib63">Parrilla-Castellar et al., 2004</xref>; <xref ref-type="bibr" rid="bib70">Sohn and Cho, 2009</xref>; <xref ref-type="bibr" rid="bib86">Xu et al., 2009</xref>). The RAD9 subunit has an N-terminal domain and a C-terminal domain connected by an inter-domain connecting loop (IDCL). Previous studies showed that RAD9 directly interacts with RPA70N through a CRD motif (checkpoint recruit domain) in the C-terminal domain; mutation of the CRD motif affected RAD9 localization and ATR checkpoint signaling (<xref ref-type="fig" rid="fig8">Figure 8A</xref>; <xref ref-type="bibr" rid="bib83">Wu et al., 2005</xref>; <xref ref-type="bibr" rid="bib85">Xu et al., 2008b</xref>). We fused the CRD to RPA70N and crystallized the fusion protein in the P3221 space group (<xref ref-type="fig" rid="fig8">Figure 8A and B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). The C-terminal part of CRD forms a short two-turn helix, while the N-terminal part adopts an extended conformation. RAD9 D297, D301 and D302 interact with RPA70N R31, R43 and R91 residues, respectively (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). RAD9 F298 inserts into the side pocket, as observed for HelB and DNA2 (<xref ref-type="fig" rid="fig8">Figures 8C</xref>, <xref ref-type="fig" rid="fig2">2D and F</xref>). Several hydrophobic residues from RAD9 (I303, M307, I308 and M310) pack with hydrophobic residues at the bottom of the RPA70N groove. ITC experiments showed that RAD9 CRD binds to RPA70N with a <italic>K<sub>D</sub></italic> of around 20.5 μM, but mutation of F298, M307 and I303 resulted in a substantially higher <italic>K<sub>D</sub></italic> value (<xref ref-type="fig" rid="fig8">Figure 8D</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A and B</xref>). In untreated HeLa cells, WT RAD9–EGFP generally colocalized with RPA. CPT or HU treatment increased the colocalization even more, while the RAD9 F298/M307/I303 triple mutant had reduced RPA–RAD9 colocalization (<xref ref-type="fig" rid="fig8">Figure 8E</xref>). This is in agreement with results obtained in U2OS cells by <xref ref-type="bibr" rid="bib85">Xu et al., 2008b</xref>, who mutated the aspartate residues in RAD9 CRD to lysine residues. The RAD9 F298/M307/I303 triple mutant pulled down much less RPA than did WT RAD9 (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). In addition, mutation of the conserved arginine residues in RPA70N (R31, R41, R43, R91) disrupted the binding of RPA70N to RAD9 peptide (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C–1F</xref>). Our results, in combination with those of previous studies, lay out the details of RPA70N/RAD9-mediated 9-1-1 clamp complex recruitment to DNA damage sites.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Structure of the RPA70N–RAD9 complex.</title><p>(<bold>A</bold>) Linear domain diagram of RAD9, showing the position and sequence of the RPA70N-interacting motif. IDCL, interdomain connecting loop. (<bold>B</bold>) Ribbon representation of the RPA70N–RAD9 crystal structure. The RAD9 peptide is colored in teal and RPA70N in light grey. Interacting residues are displayed as sticks, and green dashed lines indicate hydrogen bonds or salt bridges. (<bold>C</bold>) Structure of RPA70N in complex with RAD9, showing the surface charge of RPA70N. Hydrophobic and negatively charged residues of RAD9 are displayed as sticks, while the RAD9 peptide is colored in teal. F298 inserts into the side pocket. (<bold>D</bold>) ITC titration data for WT RAD9 (296–314aa) or F298A/M307A/I303A mutant peptide with RPA70N. (<bold>E</bold>) HeLa cells expressing RAD9–EGFP or RAD9 (F298A/M307A/I303A)–EGFP were treated with medium control, CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. The intensities of fluorescent signals for RAD9–EGFP, RAD9 (F298A/M307A/I303A)–EGFP and RPA32 are displayed on the right. (<bold>F</bold>) Immunoprecipitation and western blots show that mutation of RAD9 residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, which were followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title>Raw data for all of the western blots shown in <xref ref-type="fig" rid="fig8">Figure 8</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig8-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Characterization of the RPA70N–RAD9 interaction (related to <xref ref-type="fig" rid="fig8">Figure 8</xref>).</title><p>(<bold>A–B</bold>) ITC titration profiles of WT RAD9 (296–314aa) peptide (<bold>A</bold>) and F298A/M307A/I303A mutant peptide (<bold>B</bold>) with RPA70N. (<bold>C</bold>) ITC titration data for WT RPA70N (1–120aa) and for R31H, R91A or R41A/R43A/R91A mutant proteins with RAD9 peptide. (<bold>D–F</bold>) ITC titration profiles of RPA70N R31H mutant protein (<bold>D</bold>), R91A mutant protein (<bold>E</bold>) or R41A/R43A/R91A mutant protein (<bold>F</bold>) with RAD9 peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig8-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-8"><title>Structure of the RPA70N–ETAA1 peptide complex</title><p>ETAA1 is a newly identified ATR activator that is able to promote restart of stalled replication forks to maintain genome integrity (<xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>). ETAA1 is recruited to the DNA damage site via its two RPA-binding motifs (RBM): RBM1 interacts with RPA70N and RBM2 interacts with RPA32C (<xref ref-type="fig" rid="fig9">Figure 9A</xref>; <xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>). We fused RBM1 to RPA70N and crystallized the fusion protein in the P3221 space group (<xref ref-type="fig" rid="fig9">Figure 9A and B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). RBM1 forms a three-turn α helix with a short N-terminal extension and sits in the basic groove (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). ETAA1 D606 and D607 interact with RPA70N R31, R43 and R91. ETAA1 W600, L609, L610, Y611 and A613 pack with hydrophobic residues (I33, M57, L87, V93 and I95) from the RPA70N basic groove (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). In addition, W600 and Y611 stack with the guanidino groups from R91 and R41, respectively, to form cation-π interactions (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). ITC titration showed that the affinity between ETAA1 RBM1 and RPA70N was relatively high among peptides tested in this study, with a <italic>K<sub>D</sub></italic> of around 3.9 μM (<xref ref-type="fig" rid="fig9">Figure 9C</xref> and <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A</xref>). ETAA1 W600A/L610A/Y611A triple mutation greatly reduced the affinity between ETAA1 RBM1 and RPA70N (<xref ref-type="fig" rid="fig9">Figure 9C</xref> and <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1B</xref>). In HeLa cells, ETAA1 The W600A/L610A/Y611A triple mutant produced significantly reduced numbers of EGFP–ETAA1 and RPA foci, but triple mutant ETAA1 and RPA still have a substantial amount of colocalization (<xref ref-type="fig" rid="fig9">Figure 9D–G</xref>). This is in agreement with previous studies showing that ETAA1 has two RPA-binding motifs and that mutated RBM1 alone couldn’t completely abolish ETAA1–RPA association (<xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>). Nonetheless, our results and findings from other groups all suggest that RBM1 is required for the normal function of ETAA1 in the DNA damage response (<xref ref-type="fig" rid="fig9">Figure 9D–G</xref>; <xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>). Co-IP experiments showed reduced binding of the EGFP–ETAA1 W600A/L610A/Y611A triple mutant to RPA, and that mutation of the conserved arginine residues in RPA70N (R31, R41, R43, R91) disrupted the binding of RPA70N to the ETAA1 peptide (<xref ref-type="fig" rid="fig9">Figure 9H</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1C–1F</xref>). These data further confirmed the RPA70N–ETAA1 RBM1 interacting residues uncovered in the structure. Our results provide a structural basis for RPA70N-mediated RPA–ETAA1 interaction.</p><fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Structure of the RPA70N–ETAA1 complex.</title><p>(<bold>A</bold>) Linear domain diagram of ETAA1, showing the position and sequence of the RPA70N-interacting motif. ETAA1 has a coiled-coiled domain (CC) and two RPA-binding motifs (RBM1, RBM2). (<bold>B</bold>) Ribbon representation of the RPA70N–ETAA1 crystal structure. ETAA1 peptide is colored in bright green and RPA70N in light grey. Interface residues are shown as sticks, and green dashed lines indicate hydrogen bonds or salt bridges. (<bold>C</bold>) ITC titration data for the WT ETAA1 peptide (599–622 aa) or for the W600A/L610A/Y611A mutant peptide with RPA70N. (<bold>D</bold>) HeLa cells expressing EGFP–ETAA1 or EGFP–ETAA1(W600A/L610A/Y611A) were treated with medium control (NT), CPT (2 μM, 2 h) or HU (2 mM, 3 h), fixed and immunostained with an anti-RPA32 antibody. The scale bar is 10  μm. (<bold>E–G</bold>) Quantification of data from (<bold>D</bold>), data are presented as mean  ± s.d. of three independent experiments. 100 cells from each experiment were analyzed, and cells containing more than three bright ETAA1 and RPA co-localization foci were defined as positive. Statistical analysis was performed using a two-tailed Student’s t-test (**** <italic>P</italic>&lt;0.0001, *** <italic>P</italic>&lt;0.001, ** <italic>P</italic>&lt;0.01, * <italic>P</italic>&lt;0.05). (<bold>H</bold>) Immunoprecipitation and western blotting showed that mutation of ETAA1 residues reduced RPA association. Anti-EGFP magnetic beads were used to carry out immunoprecipitations, which were followed by probing with an anti-RPA32 antibody. IP, immunoprecipitation; WCE, whole cell extract.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Raw data for all of the western blots shown in <xref ref-type="fig" rid="fig9">Figure 9</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-81639-fig9-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig9-v1.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><label>Figure 9—figure supplement 1.</label><caption><title>Characterization of the RPA70N–ETAA1 interaction (related to <xref ref-type="fig" rid="fig9">Figure 9</xref>).</title><p>(<bold>A–B</bold>) ITC titration profiles of the WT ETAA1 (599–622 aa) peptide (<bold>A</bold>) and the W600A/L610A/Y611A mutant peptide (<bold>B</bold>) with RPA70N. (<bold>C</bold>) ITC titration data for WT RPA70N (1-120aa) and for R31H, R91A or R41A/R43A/R91A mutant proteins with ETAA1 peptide. (<bold>D–F</bold>) ITC titration profiles of RPA70N R91A mutant protein (<bold>D</bold>), R41A/R43A/R91A mutant protein (<bold>E</bold>) or R31H mutant protein (<bold>F</bold>) with ETAA1 peptide.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig9-figsupp1-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>It is well established that RPA plays important roles in DNA replication, recombination and repair (<xref ref-type="bibr" rid="bib12">Caldwell and Spies, 2020</xref>; <xref ref-type="bibr" rid="bib14">Chen and Wold, 2014</xref>; <xref ref-type="bibr" rid="bib28">Fanning et al., 2006</xref>; <xref ref-type="bibr" rid="bib42">Iftode et al., 1999</xref>; <xref ref-type="bibr" rid="bib54">Maréchal and Zou, 2015</xref>; <xref ref-type="bibr" rid="bib81">Wold, 1997</xref>; <xref ref-type="bibr" rid="bib94">Zou et al., 2006</xref>). Many RPA–protein interactions are mediated by the flexibly tethered RPA70N domain. However, RPA70N–partner interactions are often weak and highly dynamic (<xref ref-type="bibr" rid="bib12">Caldwell and Spies, 2020</xref>; <xref ref-type="bibr" rid="bib28">Fanning et al., 2006</xref>). As a result, high-resolution structures of RPA70N bound to partner peptides are rare relative to the large number of proteins that RPA70N interacts with. To overcome this problem, inspired by the fusion approach first employed by <xref ref-type="bibr" rid="bib8">Bochkareva et al., 2005</xref> to solve the RPA70N–p53 complex structure, we systematically screened RPA70N–partner fusion constructs for crystallization and determined nine complex structures of proteins involved in the DNA damage response (<xref ref-type="fig" rid="fig10">Figure 10A</xref>, <xref ref-type="fig" rid="fig1">Figure 1F–N</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Superposition of the nine structures determined in this study with apo RPA70N showed that most of the Cα atoms of RPA70N were at nearly identical positions, with RMSD values smaller than 0.3 Å (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). The L12 and L45 region displayed small conformational changes to accommodate different peptides. Overall, it appears that the interaction of RPA70N with partner protein motifs relies on the movement of side chains of the conserved positively charged and hydrophobic residues. Not surprisingly, mutation of the positively charged residues in RPA70N weakened or nearly abolished RPA70N’s ability to bind target peptides (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2C and F</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D and E</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E and F</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1C</xref>). RPA70 R31H or R31C mutation is found in some cancer patients (from the COSMIC database), which might be related to its role in protein–protein interaction. The newly solved structures also confirmed previous findings that RPA70N binds to a partner sequence through two interfaces:the basic and hydrophobic groove; and the side pocket, which is also basic and hydrophobic. The side pocket is not always used, as seen in the data for BLMp2, ATRIP, MRE11, ETAA1 and PrimPol (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). In theory, the empty side pocket could be the binding site of another peptide. This second peptide could be a not-yet-identified sequence in the protein RPA70N bound to or from another molecule. More importantly, we found that RPA70N is able to coordinate peptide binding to its two interfaces through diverse means, such as inverted direction, rotation/tilt of the bound helix, kinked conformation, or dimerization (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). The versatile interaction processes are presumably customized to the different protein sequences that RPA encounters. One could imagine that RPA70N must be able to recruit different partners under different scenarios.</p><fig-group><fig id="fig10" position="float"><label>Figure 10.</label><caption><title>Comparison of RPA70N–peptide complex structures.</title><p>(<bold>A</bold>) Summary of the RPA70N-binding proteins for which RPA70N complex structures are available (Ddc2 binds to Rfa1N). (<bold>B</bold>) Superposition of apo RPA70N (orange, PDB: 2B29) with RPA70N structures determined in this study, colored using the peptide color code used in <xref ref-type="fig" rid="fig1">Figure 1F–N</xref>.</p><p><supplementary-material id="fig10sdata1"><label>Figure 10—source data 1.</label><caption><title>Editable word file of <xref ref-type="fig" rid="fig10">Figure 10A</xref>.</title></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-81639-fig10-data1-v1.docx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig10-v1.tif"/></fig><fig id="fig10s1" position="float" specific-use="child-fig"><label>Figure 10—figure supplement 1.</label><caption><title>Model of protein recruitment in the RPA70N-mediated DNA damage response (related to <xref ref-type="fig" rid="fig10">Figure 10</xref>).</title><p>(<bold>A</bold>) A simplified model showing how exposed ssDNA attracts RPA molecules, which recruit many DNA damage response proteins including ATR/ATRIP, the 9-1-1 clamp, MRN, ETAA1 and TOPBP1 to the stalled replication fork. (<bold>B</bold>) Without ssDNA, RPA molecules are not associated with the dimeric BTR complex because of the relatively weak affinity between RPA70N and the interacting sequences in the BTR complex. (<bold>C</bold>) Multiple RPA molecules nucleate on ssDNA, the increased avidity of RPA70N promotes BTR peptides to bind, and some bound peptides in turn promote RPA70N association by interacting with two RPA70N molecules simultaneously.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81639-fig10-figsupp1-v1.tif"/></fig></fig-group><p>Of particular interest is that many of the partner peptides appear to be able to connect two RPA70N domains (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). If we expand the observed dimer, we could get a string of RPA70N domains connected by BLMp1, BLMp2 or RMI1. Intriguingly, some of these partner proteins (BTR complex, WRN, ATRIP, p53 and ETAA1) are themselves often dimers or oligomers (<xref ref-type="bibr" rid="bib15">Cho et al., 1994</xref>; <xref ref-type="bibr" rid="bib17">Compton et al., 2008</xref>; <xref ref-type="bibr" rid="bib19">Deshpande et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Hodson et al., 2022</xref>; <xref ref-type="bibr" rid="bib76">Thada and Cortez, 2021</xref>). Even for RPA70N-interacting proteins that are not dimers or oligomers, they often associate with each other directly or indirectly. For example, RPA is able to recruit ATR/ATRIP to stalled replication forks, which nucleates many RPA70N-interacting DNA damage response proteins (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1A</xref>; <xref ref-type="bibr" rid="bib4">Bass et al., 2016</xref>; <xref ref-type="bibr" rid="bib29">Feng et al., 2016</xref>; <xref ref-type="bibr" rid="bib37">Haahr et al., 2016</xref>; <xref ref-type="bibr" rid="bib49">Lee et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Maréchal and Zou, 2015</xref>; <xref ref-type="bibr" rid="bib66">Saldivar et al., 2017</xref>). <xref ref-type="bibr" rid="bib32">Frattini et al., 2021</xref> proposed the formation of a nucleation complex including RPA–ssDNA, ATR/ATRIP, TopBP1, MRN and the 9-1-1 complex, which stabilizes TopBP1 at stalled replication forks. TopBp1 in turn condensates to dynamic higher-order assemblies by multivalent cooperative interactions to achieve robust ATR activation and signal amplification (<xref ref-type="bibr" rid="bib32">Frattini et al., 2021</xref>). So there are indeed multiple copies of partner peptides in close range. One RPA usually covers around 30 nt ssDNA (<xref ref-type="bibr" rid="bib47">Kim et al., 1994</xref>); for medium to long ssDNA, there are multiple copies of bound RPA. The bridge-forming nature of some of the partner peptides in combination with many RPAs on ssDNA could greatly enhance the efficiency of partner recruitment when needed for DNA damage response (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1B and C</xref>).</p><p>Multivalent interaction processes could also serve as an intrinsic layer of regulation in addition to signal transduction pathways such as protein modifications. Under normal conditions, RPA molecules are not clustered on ssDNA and have a relatively weak affinity for many DNA damage response proteins, as shown by the dissociation constant values measured in this study and previous studies (<xref ref-type="bibr" rid="bib39">Hegnauer et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib71">Souza-Fagundes et al., 2012</xref>; <xref ref-type="bibr" rid="bib90">Yeom et al., 2019</xref>). Upon DNA damage, RPAs nucleate on exposed ssDNA quickly, owing to their sub-nanomolar affinity for ssDNA, and recruit corresponding proteins. With sufficient copies of RPA bound to ssDNA, the weak affinity of monomeric RPA70N toward target protein is now overwhelmed by multiple interaction interfaces (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1B and C</xref>). A recent study showed that RPA has a strong propensity to assemble into dynamic condensates (undergo phase separation), which is likely to be driven by RPA2 and could be stimulated by ssDNA binding (<xref ref-type="bibr" rid="bib72">Spegg et al., 2023</xref>). More importantly, the data demonstrate that RPA condensation enhances interactions with the BTR complex. The multivalent interactions that we observed in the crystal structures could contribute significantly to these condensation-driven DNA damage response processes (<xref ref-type="fig" rid="fig10s1">Figure 10—figure supplement 1B and C</xref>).</p><p>In our imaging analysis, HelB, BLM, WRN, ATRIP and ETAA1 formed a substantial number of foci and colocalized with endogenous RPA (stained with antibodies against RPA2), and this colocalization was further stimulated by CPT or HU treatment (<xref ref-type="fig" rid="fig2">Figure 2H-J</xref>, <xref ref-type="fig" rid="fig3">Figure 3J-M</xref>, <xref ref-type="fig" rid="fig5">Figure 5H-K</xref>, <xref ref-type="fig" rid="fig6">Figure 6F-J</xref>, <xref ref-type="fig" rid="fig9">Figure 9D-G</xref>). Mutation of interface residues significantly weakened the formation of foci and colocalization (<xref ref-type="fig" rid="fig2">Figure 2H-J</xref>, <xref ref-type="fig" rid="fig3">Figure 3J-M</xref>, <xref ref-type="fig" rid="fig5">Figure 5H-K</xref>, <xref ref-type="fig" rid="fig6">Figure 6F-J</xref>, <xref ref-type="fig" rid="fig9">Figure 9D-G</xref>). RMI1, MRE11 and RAD9 didn’t form distinct foci, but still colocalized with RPA to different degrees, a response that was also weakened by interface mutations (<xref ref-type="fig" rid="fig4">Figures 4G</xref>, <xref ref-type="fig" rid="fig7">7D</xref> and <xref ref-type="fig" rid="fig8">8E</xref>). Thus, it’s possible that ssDNA enriches RPA at the damage site, which promotes the association of RPA with partner proteins. At the same time, RPA70N binding to partner proteins with multivalent sites in turn promotes RPA oligomeric assembly.</p><p>In summary, the structural snapshots and biochemical analyses that we present here shed light on the diverse modes of RPA70N interacting with DNA damage response proteins. These interactions could serve to increase the avidity of RPA70N binding. Our results have provide a molecular basis for partner protein recruitment by RPA70N. Further studies with full-length RPA and RPA-interacting proteins are required to delineate the complex interaction network of RPA in DNA damage response.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Rosetta 2(DE3) chemically competent cell</td><td align="left" valign="bottom">Novagen</td><td align="left" valign="bottom">71402</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>E. coli</italic>)</td><td align="left" valign="bottom"><italic>E. coli</italic> BL21(DE3) cells</td><td align="left" valign="bottom">Novagen</td><td align="left" valign="bottom">69450</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>E. coli</italic>)</td><td align="left" valign="bottom">Trelief 5α chemically competent cell</td><td align="left" valign="bottom">TSINGKE</td><td align="left" valign="bottom">TSC-C01-100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216</td><td align="left" valign="bottom">Authenticated by STR profiling, no mycoplasma contamination</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HeLa</td><td align="left" valign="bottom">Cell bank of the Chinese Academy of Sciences</td><td align="left" valign="bottom">SCSP-504</td><td align="left" valign="bottom">Authenticated by STR profiling, no mycoplasma contamination</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GFP rabbit monoclonal antibody</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">AF1483</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RPA32 rabbit monoclonal antibody</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">AG3115</td><td align="left" valign="bottom">WB (1:2000),<break/>IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-actin mouse monoclonal antibody</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">66009–1-Ig</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-flag tag mouse monoclonal antibody</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">AF2852</td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Horseradish peroxidase labelled goat anti-mouse polyclonal secondary antibody</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">A0216</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Horseradish peroxidase labelled goat anti-rabbit polyclonal secondary antibody</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">A0208</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa 568 goat anti-rabbit polyclonal antibody IgG (H+L) cross-adsorbed secondary antibody</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A-11036</td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa 488 goat anti-mouse polyclonal antibody IgG (H+L) cross-adsorbed secondary antibody</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">A32723</td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3.1(+)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">V79020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRSFDuet-1 vector</td><td align="left" valign="bottom">Novagen</td><td align="left" valign="bottom">71341</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ClonExpress II One Step Cloning Kit</td><td align="left" valign="bottom">Vazyme</td><td align="left" valign="bottom">C112-01/02</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hydroxyurea</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">Cat#S1961</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">(S)-(+)-Camptothecin, 98%</td><td align="left" valign="bottom">J&amp;K</td><td align="left" valign="bottom">Cat#7689-03-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-(4-Amidinophenyl)–6-indolecarbamidine dihydrochloride</td><td align="left" valign="bottom">Beyotime</td><td align="left" valign="bottom">C1006</td><td align="left" valign="bottom">DAPI staining solution used to stain nucleus</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cloning, protein expression and purification</title><p>The DNA sequences of human RPA70N (residues 1–120), HelB (residues 496–519), BLMp1 (residues 146–165), BLMp2 (residues 550–570), RMI1 (residues 243–262), WRN (residues 435–451), ATRIP (residues 53–69), MRE11 (residues 538–563), RAD9 (residues 296–314) and ETAA1 (residues 599–622) were individually cloned into a modified pRSFDuet-1 vector (Novagen). This vector fuses an N-terminal 6-His-sumo tag to the target gene using ClonExpress II One Step Cloning Kit (Vazyme). RPA70N–peptide fusion constructs were cloned into the same expression vector. RPA70N, RPA70N–peptide fusion proteins and all peptides were expressed and purified with similar steps. The recombinant plasmids were transformed into <italic>E. coli</italic> BL21(DE3) cells or Rosetta 2 (DE3) cells (Novagen), which were grown in LB medium at 37 °C until the OD 600 reached 0.6–0.8. Overexpression of proteins was induced by the addition of 0.5 mM isopropyl β-D-thiogalactopyranoside (IPTG), followed by incubation at 20 °C for 14 h. Cells were harvested by centrifugation, resuspended in lysis buffer (20 mM Tris-HCl, 200 mM NaCl, 20 mM imdazole, 10% glycerol, 0.3 mM TCEP, pH 8.0), and lysed by a high-pressure homogenizer at 4 °C. The cell lysate was centrifuged at 12,000 rpm for 40 min to obtain soluble extract. After nickel affinity pull-down, 6-His-sumo tag was cleaved off by Ulp1 protease and removed by a second nickel column. Flow-through was then passed through a Source 15Q column (Cytiva) and eluted with a gradient of 0–1 M NaCl in a buffer of 20 mM Tris-HCl, pH 8.0, 10% glycerol, 0.3 mM TCEP. Fractions containing target proteins were pooled and concentrated, then further purified on a Superdex 75 increase gel filtration column (Cytiva) in a buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.3 mM TCEP. The purified RPA70N–peptide fusion proteins were concentrated to around 20–25 mg/ml for crystallization. RPA70N and all peptides were concentrated to suitable concentrations for ITC titrations.</p></sec><sec id="s4-2"><title>Crystallization</title><p>For all of the RPA70N–peptide fusion proteins, crystallization screenings were performed using 96-well plates in a sitting drop mode at 4℃. The RPA70N–HelB fusion protein crystallized in 20% (w/v) PEG 3350, 200 mM calcium chloride. The RPA70N-BLMp1 fusion protein crystallized in 100 mM sodium citrate pH 5.6, 2000 mM ammonium sulfate, 200 mM potassium/sodium tartrate. RPA70N–BLMp2 fusion protein crystallized in 100 mM sodium acetate pH 4.6, 8% (w/v) PEG 4000. The RPA70–WRN fusion protein crystallized in 20% (w/v) PEG 3350, 200 mM ammonium sulfate. The RPA70N–RMI1 fusion protein crystallized in 100 mM sodium acetate pH 4.6, 30% (w/v) PEG 2000 MME, 200 mM ammonium sulfate. The RPA70N–ATRIP fusion protein crystallized in 100 mM Tris-HCl pH 8.5, 2400 mM ammonium sulfate. The RPA70N–MRE11 fusion protein crystallized in 100 mM HEPES pH 7.5, 1260 mM ammonium sulfate. The RPA70N–RAD9 fusion protein crystallized in 100 mM sodium acetate pH 4.6, 25% (w/v) PEG 4000, 200 mM ammonium sulfate. The RPA70N–ETAA1 fusion protein crystallized in 20% (w/v) PEG 3350, 200 mM ammonium chloride. Crystals were cryo-protected in their respective well solutions supplemented with 20% ethylene glycol and flash-frozen in liquid nitrogen.</p></sec><sec id="s4-3"><title>Structure determination and refinement</title><p>Diffraction data were collected at Beamline stations BL17U1, BL18U1 and BL19U1 at Shanghai Synchrotron Radiation Facility (SSRF, Shanghai, China). The data were integrated and scaled using XDS, the CCP4 program Pointless and Aimless (<xref ref-type="bibr" rid="bib25">Evans and Murshudov, 2013</xref>; <xref ref-type="bibr" rid="bib44">Kabsch, 2010</xref>; <xref ref-type="bibr" rid="bib80">Winn et al., 2011</xref>). The structures of RPA70N–peptide fusion constructs were determined by molecular replacement using the RPA70N structure from PDB 5EAY as an initial searching model with Phaser (<xref ref-type="bibr" rid="bib55">McCoy et al., 2007</xref>). The structural model was built using Coot (<xref ref-type="bibr" rid="bib24">Emsley and Cowtan, 2004</xref>) and refined using PHENIX (<xref ref-type="bibr" rid="bib52">Liebschner et al., 2019</xref>). Figures were generated using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). The statistics for the data collection and refinement are shown in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>.</p></sec><sec id="s4-4"><title>Isothermal titration calorimetry (ITC)</title><p>All ITC titrations were carried out using a MicroCal PEAQ-ITC instrument (Malvern) at 25 °C with different peptides in the syringe and RPA70N in the cell. RPA70N and peptide samples were dialyzed against a working buffer consisting of 20 mM HEPES, 100 mM NaCl, 1 mM DTT, pH 7.5. Each titration was carried out with 19 injections, spaced 150 s apart, stir speed at 500 rpm. The acquired calorimetric titration data were analyzed with Origin 7.0 software using the ‘One Set of Binding Sites’ fitting model.</p></sec><sec id="s4-5"><title>Cell culture</title><p>HeLa cells (SCSP-504, Cell bank of the Chinese Academy of Sciences) and HEK293T (CRL-3216, ATCC) cells used in this study were authenticated by STR (short tandem repeat) profiling and tested negative for mycoplasma contamination. They were cultured at 37 °C with 5% CO<sub>2</sub> in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (ExCell Bio), 100 units/ml penicillin, and 100  μg/ml streptomycin. HeLa cells and HEK293T cells were seeded into glass-bottom dishes and cultured overnight. The next day, 1–2 µg of each plasmid and 3–6 µL of PEI reagent (Polyscience) were mixed and transferred to each well for transient transfection.</p></sec><sec id="s4-6"><title>Antibodies</title><p>The following antibodies were used in this study: anti-GFP rabbit monoclonal antibody (Beyotime, AF1483), anti-RPA32 rabbit monoclonal antibody (Beyotime, AG3115), anti-FLAG tag mouse monoclonal antibody (Beyotime, AF2852), anti-β-actin monoclonal antibody (Proteintech, 66009–1-Ig), goat anti-rabbit polyclonal secondary antibody IgG (Beyotime, A0208), goat anti-mouse polyclonal secondary antibody IgG (Beyotime, A0216), Alexa 568 goat anti-rabbit polyclonal IgG (H+L) cross-adsorbed secondary antibody (Thermo, A_11036), Alexa 488 goat anti-mouse polyclonal IgG (H+L) cross-adsorbed secondary antibody (Thermo, A32723).</p></sec><sec id="s4-7"><title>Immunofluorescence</title><p>HeLa cells were transiently transfected with HelB–EGFP, EGFP–BLM, EGFP–RMI1, WRN–EGFP, ATRIP–EGFP, MRE11–FLAG, RAD9–EGFP, or EGFP–ETAA1 plasmids (pcDNA3.1(+)). The day after transfection, cells were treated with hydroxyurea (HU) or camptothecin (CPT) for 2–3 hours. Then the cells were washed with phosphate-buffered saline (PBS), fixed with 4% (w/v) paraformaldehyde for 10 min at room temperature, and blocked with QuickBlock blocking buffer (Beyotime). Fixed cells were incubated overnight with an anti-RPA32 antibody (Beyotime) diluted 1:200 in blocking buffer at 4 °C. Then, cells were incubated for 1 h at room temperature in the dark with Alexa Fluor 488 anti-mouse or 568 anti-rabbit secondary antibodies diluted 1:400 in blocking buffer. After that, cells were stained with DAPI staining solution (Beyotime) for 5 min. Finally, they were mounted in a fluorescence quenching solution and imaged on a Nikon C2 confocal microscope. The images of cells excited with individual fluorescent channels were taken separately and merged afterward with Nikon imaging software. For MRE11-FLAG, an anti-FLAG antibody (Beyotime) was also used for immunostaining.</p></sec><sec id="s4-8"><title>Immunoprecipitations</title><p>DNA sequences of HelB–EGFP, EGFP–BLM, EGFP–RMI1, EGFP–WRN, EGFP–ATRIP, EGFP–ETAA1, RAD9–EGFP, or EGFP–MRE11 were cloned into the plasmid pcDNA3.1(+). 48 h after transfection, HEK 293T cells were washed with phosphate-buffered saline (PBS) and lysed in IP buffer comprising 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 5% w/v glycerol, ultraNuclease (Yeasen), and 1×PMSF and protease inhibitor cocktail (Topscience). For IP reactions, cleared cell lysates were incubated with anti-GFP magnetic beads (Beyotime) for 4 h at 4 °C with rotation. The beads were washed three times with tris buffered saline (TBS) using a magnetic separator. The bound proteins were eluted with 50 μl 5×SDS-loading buffer. Samples were boiled at 95 °C for 5 min and separated with 10% SDS-PAGE gels for immunoblot analysis.</p></sec><sec id="s4-9"><title>Western blotting</title><p>Samples were run on 10% SDS-PAGE gels and transferred in a tris-glycine transfer buffer containing 20% methanol and 0.01% SDS onto PVDF membranes. Membranes were blocked using 5% BSA in TBST and incubated with primary antibodies overnight at 4 °C with 5% BSA in TBST. After three washes with TBST, membranes were incubated for 1 h at room temperature with secondary antibodies. Afterward, membranes were washed three times in TBST and imaged (Azure Biosystem C400).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81639-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Atomic coordinates and structure factors for the reported crystal structures have been deposited with the Protein Data Bank under accession number: 7XUT, 7XUV, 7XUW, 7XV0, 7XV1, 7XV4, 8JZV, 8JZY, 8K00.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-WRN fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xut/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-RMI1 fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xuv/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-BLMp2 fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xuw/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-BLMp1 fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xv0/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-HelB fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xv1/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset6"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Crystal structure of RPA70N-ATRIP fusion</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb7xv4/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset7"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>RPA70N_ETAA1_8JZV</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb8jzv/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset8"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>RPA70N_RAD9_8JZY</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb8jzy/pdb</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset9"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Zang</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>RPA70N_MRE11_ 8K00</data-title><source>Worldwide Protein Data Bank</source><pub-id pub-id-type="doi">10.2210/pdb8k00/pdb</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the staff at SSRF BL19U1, BL17U1 and BL18U1 for the collection of X-ray diffraction data. We thank the staff at the National Facility for Protein Science in Shanghai (NFPS) and Westlake University Biomedical Research Core Facilities for assistance with ITC experiments. We thank Dr. Nikola Pavletich for helpful discussions. We thank Dr. Jie Sun, Dr. Ying Gu, Dr. Yuyuan Zheng, Dr. Panyu Fei and members of Zhou Lab for their kind help. This work was supported by the National Natural Science Foundation of China (31971125 to CZ).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramova</surname><given-names>NA</given-names></name><name><surname>Russell</surname><given-names>J</given-names></name><name><surname>Botchan</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Interaction between replication protein A and p53 is disrupted after UV damage in A DNA repair-dependent manner</article-title><source>PNAS</source><volume>94</volume><fpage>7186</fpage><lpage>7191</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.14.7186</pub-id><pub-id pub-id-type="pmid">9207066</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awate</surname><given-names>S</given-names></name><name><surname>Brosh</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interactive Roles of DNA Helicases and Translocases with the Single-Stranded DNA Binding Protein RPA in Nucleic Acid Metabolism</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>1233</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18061233</pub-id><pub-id pub-id-type="pmid">28594346</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>HL</given-names></name><name><surname>Myers</surname><given-names>JS</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation</article-title><source>Molecular Biology of the Cell</source><volume>16</volume><fpage>2372</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1091/mbc.e04-11-1006</pub-id><pub-id pub-id-type="pmid">15743907</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bass</surname><given-names>TE</given-names></name><name><surname>Luzwick</surname><given-names>JW</given-names></name><name><surname>Kavanaugh</surname><given-names>G</given-names></name><name><surname>Carroll</surname><given-names>C</given-names></name><name><surname>Dungrawala</surname><given-names>H</given-names></name><name><surname>Glick</surname><given-names>GG</given-names></name><name><surname>Feldkamp</surname><given-names>MD</given-names></name><name><surname>Putney</surname><given-names>R</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ETAA1 acts at stalled replication forks to maintain genome integrity</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>1185</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1038/ncb3415</pub-id><pub-id pub-id-type="pmid">27723720</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>LJ</given-names></name><name><surname>Borowiec</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Human replication protein A binds single-stranded DNA in two distinct complexes</article-title><source>Molecular and Cellular Biology</source><volume>14</volume><fpage>3993</fpage><lpage>4001</lpage><pub-id pub-id-type="doi">10.1128/mcb.14.6.3993-4001.1994</pub-id><pub-id pub-id-type="pmid">8196638</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochkarev</surname><given-names>A</given-names></name><name><surname>Pfuetzner</surname><given-names>RA</given-names></name><name><surname>Edwards</surname><given-names>AM</given-names></name><name><surname>Frappier</surname><given-names>L</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA</article-title><source>Nature</source><volume>385</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/385176a0</pub-id><pub-id pub-id-type="pmid">8990123</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochkareva</surname><given-names>E</given-names></name><name><surname>Korolev</surname><given-names>S</given-names></name><name><surname>Lees-Miller</surname><given-names>SP</given-names></name><name><surname>Bochkarev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Structure of the RPA trimerization core and its role in the multistep DNA-binding mechanism of RPA</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>1855</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.7.1855</pub-id><pub-id pub-id-type="pmid">11927569</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bochkareva</surname><given-names>E</given-names></name><name><surname>Kaustov</surname><given-names>L</given-names></name><name><surname>Ayed</surname><given-names>A</given-names></name><name><surname>Yi</surname><given-names>GS</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Pineda-Lucena</surname><given-names>A</given-names></name><name><surname>Liao</surname><given-names>JCC</given-names></name><name><surname>Okorokov</surname><given-names>AL</given-names></name><name><surname>Milner</surname><given-names>J</given-names></name><name><surname>Arrowsmith</surname><given-names>CH</given-names></name><name><surname>Bochkarev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A</article-title><source>PNAS</source><volume>102</volume><fpage>15412</fpage><lpage>15417</lpage><pub-id pub-id-type="doi">10.1073/pnas.0504614102</pub-id><pub-id pub-id-type="pmid">16234232</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosh</surname><given-names>RM</given-names></name><name><surname>Orren</surname><given-names>DK</given-names></name><name><surname>Nehlin</surname><given-names>JO</given-names></name><name><surname>Ravn</surname><given-names>PH</given-names></name><name><surname>Kenny</surname><given-names>MK</given-names></name><name><surname>Machwe</surname><given-names>A</given-names></name><name><surname>Bohr</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Functional and physical interaction between WRN helicase and human replication protein A</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>18341</fpage><lpage>18350</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.26.18341</pub-id><pub-id pub-id-type="pmid">10373438</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosh</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Kenny</surname><given-names>MK</given-names></name><name><surname>Karow</surname><given-names>JK</given-names></name><name><surname>Cooper</surname><given-names>MP</given-names></name><name><surname>Kureekattil</surname><given-names>RP</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name><name><surname>Bohr</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Replication protein A physically interacts with the Bloom’s syndrome protein and stimulates its helicase activity</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>23500</fpage><lpage>23508</lpage><pub-id pub-id-type="doi">10.1074/jbc.M001557200</pub-id><pub-id pub-id-type="pmid">10825162</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bythell-Douglas</surname><given-names>R</given-names></name><name><surname>Deans</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A structural guide to the bloom syndrome complex</article-title><source>Structure</source><volume>29</volume><fpage>99</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.str.2020.11.020</pub-id><pub-id pub-id-type="pmid">33357470</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>CC</given-names></name><name><surname>Spies</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dynamic elements of replication protein A at the crossroads of DNA replication, recombination, and repair</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><volume>55</volume><fpage>482</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1080/10409238.2020.1813070</pub-id><pub-id pub-id-type="pmid">32856505</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejka</surname><given-names>P</given-names></name><name><surname>Cannavo</surname><given-names>E</given-names></name><name><surname>Polaczek</surname><given-names>P</given-names></name><name><surname>Masuda-Sasa</surname><given-names>T</given-names></name><name><surname>Pokharel</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>JL</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>DNA end resection by Dna2-Sgs1-RPA and its stimulation by Top3-Rmi1 and Mre11-Rad50-Xrs2</article-title><source>Nature</source><volume>467</volume><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1038/nature09355</pub-id><pub-id pub-id-type="pmid">20811461</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Replication protein A: single-stranded DNA’s first responder: dynamic DNA-interactions allow replication protein A to direct single-strand DNA intermediates into different pathways for synthesis or repair</article-title><source>BioEssays</source><volume>36</volume><fpage>1156</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1002/bies.201400107</pub-id><pub-id pub-id-type="pmid">25171654</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Gorina</surname><given-names>S</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations</article-title><source>Science</source><volume>265</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1126/science.8023157</pub-id><pub-id pub-id-type="pmid">8023157</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>WK</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>RecQ helicases: multifunctional genome caretakers</article-title><source>Nature Reviews. Cancer</source><volume>9</volume><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1038/nrc2682</pub-id><pub-id pub-id-type="pmid">19657341</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>SA</given-names></name><name><surname>Tolun</surname><given-names>G</given-names></name><name><surname>Kamath-Loeb</surname><given-names>AS</given-names></name><name><surname>Loeb</surname><given-names>LA</given-names></name><name><surname>Griffith</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The Werner syndrome protein binds replication fork and holliday junction DNAs as an oligomer</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>24478</fpage><lpage>24483</lpage><pub-id pub-id-type="doi">10.1074/jbc.M803370200</pub-id><pub-id pub-id-type="pmid">18596042</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croteau</surname><given-names>DL</given-names></name><name><surname>Popuri</surname><given-names>V</given-names></name><name><surname>Opresko</surname><given-names>PL</given-names></name><name><surname>Bohr</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Human RecQ helicases in DNA repair, recombination, and replication</article-title><source>Annual Review of Biochemistry</source><volume>83</volume><fpage>519</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060713-035428</pub-id><pub-id pub-id-type="pmid">24606147</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>I</given-names></name><name><surname>Seeber</surname><given-names>A</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Keusch</surname><given-names>JJ</given-names></name><name><surname>Gut</surname><given-names>H</given-names></name><name><surname>Gasser</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structural Basis of Mec1-Ddc2-RPA Assembly and Activation on Single-Stranded DNA at Sites of Damage</article-title><source>Molecular Cell</source><volume>68</volume><fpage>431</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.019</pub-id><pub-id pub-id-type="pmid">29033322</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname><given-names>KM</given-names></name><name><surname>Sommers</surname><given-names>JA</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>von Kobbe</surname><given-names>C</given-names></name><name><surname>Thoma</surname><given-names>NH</given-names></name><name><surname>Kureekattil</surname><given-names>RP</given-names></name><name><surname>Kenny</surname><given-names>MK</given-names></name><name><surname>Brosh</surname><given-names>RM</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2005">2005</year><article-title>Physical and functional mapping of the replication protein a interaction domain of the werner and bloom syndrome helicases</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>29494</fpage><lpage>29505</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500653200</pub-id><pub-id pub-id-type="pmid">15965237</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doré</surname><given-names>AS</given-names></name><name><surname>Kilkenny</surname><given-names>ML</given-names></name><name><surname>Rzechorzek</surname><given-names>NJ</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystal structure of the rad9-rad1-hus1 DNA damage checkpoint complex--implications for clamp loading and regulation</article-title><source>Molecular Cell</source><volume>34</volume><fpage>735</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.04.027</pub-id><pub-id pub-id-type="pmid">19446481</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dornreiter</surname><given-names>I</given-names></name><name><surname>Erdile</surname><given-names>LF</given-names></name><name><surname>Gilbert</surname><given-names>IU</given-names></name><name><surname>von Winkler</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>TJ</given-names></name><name><surname>Fanning</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Interaction of DNA polymerase alpha-primase with cellular replication protein A and SV40 T antigen</article-title><source>The EMBO Journal</source><volume>11</volume><fpage>769</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1992.tb05110.x</pub-id><pub-id pub-id-type="pmid">1311258</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>A</given-names></name><name><surname>Ruppert</surname><given-names>JM</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Winchester</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Inhibition of DNA replication factor RPA by p53</article-title><source>Nature</source><volume>365</volume><fpage>79</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1038/365079a0</pub-id><pub-id pub-id-type="pmid">8361542</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>60</volume><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1107/S0907444904019158</pub-id><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>How good are my data and what is the resolution?</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>69</volume><fpage>1204</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1107/S0907444913000061</pub-id><pub-id pub-id-type="pmid">23793146</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairman</surname><given-names>MP</given-names></name><name><surname>Stillman</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Cellular factors required for multiple stages of SV40 DNA replication in vitro</article-title><source>The EMBO Journal</source><volume>7</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1988.tb02933.x</pub-id><pub-id pub-id-type="pmid">2841119</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structure and conformational change of A replication protein A heterotrimer bound to ssDNA</article-title><source>Genes &amp; Development</source><volume>26</volume><fpage>2337</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1101/gad.194787.112</pub-id><pub-id pub-id-type="pmid">23070815</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanning</surname><given-names>E</given-names></name><name><surname>Klimovich</surname><given-names>V</given-names></name><name><surname>Nager</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A dynamic model for replication protein A (RPA) function in DNA processing pathways</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>4126</fpage><lpage>4137</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl550</pub-id><pub-id pub-id-type="pmid">16935876</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>S</given-names></name><name><surname>Huo</surname><given-names>W</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ewing tumor-associated antigen 1 interacts with replication protein A to promote restart of stalled replication forks</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>21956</fpage><lpage>21962</lpage><pub-id pub-id-type="doi">10.1074/jbc.C116.747758</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>RL</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oligonucleotide/oligosaccharide-binding fold proteins: a growing family of genome guardians</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><volume>45</volume><fpage>266</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.3109/10409238.2010.488216</pub-id><pub-id pub-id-type="pmid">20515430</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>AO</given-names></name><name><surname>Vangamudi</surname><given-names>B</given-names></name><name><surname>Feldkamp</surname><given-names>MD</given-names></name><name><surname>Souza-Fagundes</surname><given-names>EM</given-names></name><name><surname>Luzwick</surname><given-names>JW</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Waterson</surname><given-names>AG</given-names></name><name><surname>Rossanese</surname><given-names>OW</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery of A potent stapled helix peptide that binds to the 70N domain of replication protein A</article-title><source>Journal of Medicinal Chemistry</source><volume>57</volume><fpage>2455</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1021/jm401730y</pub-id><pub-id pub-id-type="pmid">24491171</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frattini</surname><given-names>C</given-names></name><name><surname>Promonet</surname><given-names>A</given-names></name><name><surname>Alghoul</surname><given-names>E</given-names></name><name><surname>Vidal-Eychenie</surname><given-names>S</given-names></name><name><surname>Lamarque</surname><given-names>M</given-names></name><name><surname>Blanchard</surname><given-names>MP</given-names></name><name><surname>Urbach</surname><given-names>S</given-names></name><name><surname>Basbous</surname><given-names>J</given-names></name><name><surname>Constantinou</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>TopBP1 assembles nuclear condensates to switch on ATR signaling</article-title><source>Molecular Cell</source><volume>81</volume><fpage>1231</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.12.049</pub-id><pub-id pub-id-type="pmid">33503405</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravel</surname><given-names>S</given-names></name><name><surname>Chapman</surname><given-names>JR</given-names></name><name><surname>Magill</surname><given-names>C</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>DNA helicases Sgs1 and BLM promote DNA double-strand break resection</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>2767</fpage><lpage>2772</lpage><pub-id pub-id-type="doi">10.1101/gad.503108</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilliam</surname><given-names>TA</given-names></name><name><surname>Brissett</surname><given-names>NC</given-names></name><name><surname>Ehlinger</surname><given-names>A</given-names></name><name><surname>Keen</surname><given-names>BA</given-names></name><name><surname>Kolesar</surname><given-names>P</given-names></name><name><surname>Taylor</surname><given-names>EM</given-names></name><name><surname>Bailey</surname><given-names>LJ</given-names></name><name><surname>Lindsay</surname><given-names>HD</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Doherty</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular basis for PrimPol recruitment to replication forks by RPA</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15222</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15222</pub-id><pub-id pub-id-type="pmid">28534480</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guler</surname><given-names>GD</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Vaithiyalingam</surname><given-names>S</given-names></name><name><surname>Arnett</surname><given-names>DR</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Fanning</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Human DNA helicase B (HDHB) binds to replication protein A and facilitates cellular recovery from replication stress</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>6469</fpage><lpage>6481</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.324582</pub-id><pub-id pub-id-type="pmid">22194613</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Sommers</surname><given-names>JA</given-names></name><name><surname>Kenny</surname><given-names>MK</given-names></name><name><surname>Cantor</surname><given-names>SB</given-names></name><name><surname>Brosh</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein</article-title><source>Blood</source><volume>110</volume><fpage>2390</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-11-057273</pub-id><pub-id pub-id-type="pmid">17596542</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haahr</surname><given-names>P</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><name><surname>Tollenaere</surname><given-names>MAX</given-names></name><name><surname>Ho</surname><given-names>T</given-names></name><name><surname>Toledo</surname><given-names>LI</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name><name><surname>Räschle</surname><given-names>M</given-names></name><name><surname>Mailand</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation of the ATR kinase by the RPA-binding protein ETAA1</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>1196</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1038/ncb3422</pub-id><pub-id pub-id-type="pmid">27723717</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazeslip</surname><given-names>L</given-names></name><name><surname>Zafar</surname><given-names>MK</given-names></name><name><surname>Chauhan</surname><given-names>MZ</given-names></name><name><surname>Byrd</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genome Maintenance by DNA Helicase B</article-title><source>Genes</source><volume>11</volume><elocation-id>578</elocation-id><pub-id pub-id-type="doi">10.3390/genes11050578</pub-id><pub-id pub-id-type="pmid">32455610</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegnauer</surname><given-names>AM</given-names></name><name><surname>Hustedt</surname><given-names>N</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Pike</surname><given-names>BL</given-names></name><name><surname>Vogel</surname><given-names>M</given-names></name><name><surname>Amsler</surname><given-names>P</given-names></name><name><surname>Rubin</surname><given-names>SM</given-names></name><name><surname>van Leeuwen</surname><given-names>F</given-names></name><name><surname>Guénolé</surname><given-names>A</given-names></name><name><surname>van Attikum</surname><given-names>H</given-names></name><name><surname>Thomä</surname><given-names>NH</given-names></name><name><surname>Gasser</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An N-terminal acidic region of Sgs1 interacts with Rpa70 and recruits Rad53 kinase to stalled forks</article-title><source>The EMBO Journal</source><volume>31</volume><fpage>3768</fpage><lpage>3783</lpage><pub-id pub-id-type="doi">10.1038/emboj.2012.195</pub-id><pub-id pub-id-type="pmid">22820947</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodson</surname><given-names>C</given-names></name><name><surname>Low</surname><given-names>JKK</given-names></name><name><surname>van Twest</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name><name><surname>Swuec</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>V</given-names></name><name><surname>Tsukada</surname><given-names>K</given-names></name><name><surname>Fawkes</surname><given-names>M</given-names></name><name><surname>Bythell-Douglas</surname><given-names>R</given-names></name><name><surname>Davies</surname><given-names>A</given-names></name><name><surname>Holien</surname><given-names>JK</given-names></name><name><surname>O’Rourke</surname><given-names>JJ</given-names></name><name><surname>Parker</surname><given-names>BL</given-names></name><name><surname>Glaser</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>MW</given-names></name><name><surname>Mackay</surname><given-names>JP</given-names></name><name><surname>Blackford</surname><given-names>AN</given-names></name><name><surname>Costa</surname><given-names>A</given-names></name><name><surname>Deans</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mechanism of Bloom syndrome complex assembly required for double Holliday junction dissolution and genome stability</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2109093119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2109093119</pub-id><pub-id pub-id-type="pmid">35115399</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hormeno</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>OJ</given-names></name><name><surname>Aicart-Ramos</surname><given-names>C</given-names></name><name><surname>Kuppa</surname><given-names>S</given-names></name><name><surname>Antony</surname><given-names>E</given-names></name><name><surname>Dillingham</surname><given-names>MS</given-names></name><name><surname>Moreno-Herrero</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Human HELB is a processive motor protein that catalyzes RPA clearance from single-stranded DNA</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2112376119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2112376119</pub-id><pub-id pub-id-type="pmid">35385349</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iftode</surname><given-names>C</given-names></name><name><surname>Daniely</surname><given-names>Y</given-names></name><name><surname>Borowiec</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Replication protein A (RPA): the eukaryotic SSB</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><volume>34</volume><fpage>141</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1080/10409239991209255</pub-id><pub-id pub-id-type="pmid">10473346</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>DM</given-names></name><name><surname>Lipton</surname><given-names>AS</given-names></name><name><surname>Isern</surname><given-names>NG</given-names></name><name><surname>Daughdrill</surname><given-names>GW</given-names></name><name><surname>Lowry</surname><given-names>DF</given-names></name><name><surname>Gomes</surname><given-names>X</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Human replication protein A: global fold of the N-terminal RPA-70 domain reveals A basic cleft and flexible C-terminal linker</article-title><source>Journal of Biomolecular NMR</source><volume>14</volume><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1023/a:1008373009786</pub-id><pub-id pub-id-type="pmid">10526407</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabsch</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>XDS</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>66</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1107/S0907444909047337</pub-id><pub-id pub-id-type="pmid">20124692</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>KS</given-names></name><name><surname>Cheong</surname><given-names>HK</given-names></name><name><surname>Kim</surname><given-names>EH</given-names></name><name><surname>Park</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interaction of replication protein A with two acidic peptides from human Bloom syndrome protein</article-title><source>FEBS Letters</source><volume>592</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.12992</pub-id><pub-id pub-id-type="pmid">29388204</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Snyder</surname><given-names>RO</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Binding properties of replication protein A from human and yeast cells</article-title><source>Molecular and Cellular Biology</source><volume>12</volume><fpage>3050</fpage><lpage>3059</lpage><pub-id pub-id-type="doi">10.1128/mcb.12.7.3050-3059.1992</pub-id><pub-id pub-id-type="pmid">1320195</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Paulus</surname><given-names>BF</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Interactions of human replication protein A with oligonucleotides</article-title><source>Biochemistry</source><volume>33</volume><fpage>14197</fpage><lpage>14206</lpage><pub-id pub-id-type="doi">10.1021/bi00251a031</pub-id><pub-id pub-id-type="pmid">7947831</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitano</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural mechanisms of human RecQ helicases WRN and BLM</article-title><source>Frontiers in Genetics</source><volume>5</volume><elocation-id>366</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2014.00366</pub-id><pub-id pub-id-type="pmid">25400656</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RPA-Binding Protein ETAA1 Is an ATR Activator Involved in DNA Replication Stress Response</article-title><source>Current Biology</source><volume>26</volume><fpage>3257</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2016.10.030</pub-id><pub-id pub-id-type="pmid">27818175</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Uhm</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Kirk</surname><given-names>J</given-names></name><name><surname>Hyun</surname><given-names>K</given-names></name><name><surname>Kulikowicz</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>B</given-names></name><name><surname>Bohr</surname><given-names>VA</given-names></name><name><surname>Hohng</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Multiple RPAs make WRN syndrome protein a superhelicase</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>4689</fpage><lpage>4698</lpage><pub-id pub-id-type="doi">10.1093/nar/gky272</pub-id><pub-id pub-id-type="pmid">29668972</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Botchan</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV-1 DNA replication</article-title><source>Cell</source><volume>73</volume><fpage>1207</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90649-b</pub-id><pub-id pub-id-type="pmid">8390328</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Baker</surname><given-names>ML</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Croll</surname><given-names>TI</given-names></name><name><surname>Hintze</surname><given-names>B</given-names></name><name><surname>Hung</surname><given-names>LW</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Moriarty</surname><given-names>NW</given-names></name><name><surname>Oeffner</surname><given-names>RD</given-names></name><name><surname>Poon</surname><given-names>BK</given-names></name><name><surname>Prisant</surname><given-names>MG</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Richardson</surname><given-names>JS</given-names></name><name><surname>Richardson</surname><given-names>DC</given-names></name><name><surname>Sammito</surname><given-names>MD</given-names></name><name><surname>Sobolev</surname><given-names>OV</given-names></name><name><surname>Stockwell</surname><given-names>DH</given-names></name><name><surname>Terwilliger</surname><given-names>TC</given-names></name><name><surname>Urzhumtsev</surname><given-names>AG</given-names></name><name><surname>Videau</surname><given-names>LL</given-names></name><name><surname>Williams</surname><given-names>CJ</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>75</volume><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="doi">10.1107/S2059798319011471</pub-id><pub-id pub-id-type="pmid">31588918</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Vaithiyalingam</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Zinkel</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BID binds to replication protein A and stimulates ATR function following replicative stress</article-title><source>Molecular and Cellular Biology</source><volume>31</volume><fpage>4298</fpage><lpage>4309</lpage><pub-id pub-id-type="doi">10.1128/MCB.05737-11</pub-id><pub-id pub-id-type="pmid">21859891</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maréchal</surname><given-names>A</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response</article-title><source>Cell Research</source><volume>25</volume><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/cr.2014.147</pub-id><pub-id pub-id-type="pmid">25403473</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Storoni</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Phaser crystallographic software</article-title><source>Journal of Applied Crystallography</source><volume>40</volume><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Sinha</surname><given-names>D</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Srinivasan</surname><given-names>K</given-names></name><name><surname>Abdisalaam</surname><given-names>S</given-names></name><name><surname>Asaithamby</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Werner Syndrome Protein and DNA Replication</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>3442</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113442</pub-id><pub-id pub-id-type="pmid">30400178</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murzin</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences</article-title><source>The EMBO Journal</source><volume>12</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb05726.x</pub-id><pub-id pub-id-type="pmid">8458342</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namiki</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>ATRIP associates with replication protein A-coated ssDNA through multiple interactions</article-title><source>PNAS</source><volume>103</volume><fpage>580</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510223103</pub-id><pub-id pub-id-type="pmid">16407120</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimonkar</surname><given-names>AV</given-names></name><name><surname>Genschel</surname><given-names>J</given-names></name><name><surname>Kinoshita</surname><given-names>E</given-names></name><name><surname>Polaczek</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>JL</given-names></name><name><surname>Wyman</surname><given-names>C</given-names></name><name><surname>Modrich</surname><given-names>P</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>350</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1101/gad.2003811</pub-id><pub-id pub-id-type="pmid">21325134</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>B</given-names></name><name><surname>Feldkamp</surname><given-names>MD</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Friedman</surname><given-names>KL</given-names></name><name><surname>Fanning</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Simian virus Large T antigen interacts with the N-terminal domain of the 70 kD subunit of Replication Protein A in the same mode as multiple DNA damage response factors</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0116093</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0116093</pub-id><pub-id pub-id-type="pmid">25706313</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>GG</given-names></name><name><surname>Tillison</surname><given-names>K</given-names></name><name><surname>Opiyo</surname><given-names>SA</given-names></name><name><surname>Glanzer</surname><given-names>JG</given-names></name><name><surname>Horn</surname><given-names>JM</given-names></name><name><surname>Patrick</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Physical interaction between replication protein A (RPA) and MRN: involvement of RPA2 phosphorylation and the N-terminus of RPA1</article-title><source>Biochemistry</source><volume>48</volume><fpage>7473</fpage><lpage>7481</lpage><pub-id pub-id-type="doi">10.1021/bi900694p</pub-id><pub-id pub-id-type="pmid">19586055</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Nievera</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>AY-L</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The Mre11 complex mediates the S-phase checkpoint through an interaction with replication protein A</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>6053</fpage><lpage>6067</lpage><pub-id pub-id-type="doi">10.1128/MCB.00532-07</pub-id><pub-id pub-id-type="pmid">17591703</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrilla-Castellar</surname><given-names>ER</given-names></name><name><surname>Arlander</surname><given-names>SJH</given-names></name><name><surname>Karnitz</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex</article-title><source>DNA Repair</source><volume>3</volume><fpage>1009</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2004.03.032</pub-id><pub-id pub-id-type="pmid">15279787</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robison</surname><given-names>JG</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Dixon</surname><given-names>K</given-names></name><name><surname>Oakley</surname><given-names>GG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Replication protein A and the Mre11.Rad50.Nbs1 complex co-localize and interact at sites of stalled replication forks</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>34802</fpage><lpage>34810</lpage><pub-id pub-id-type="doi">10.1074/jbc.M404750200</pub-id><pub-id pub-id-type="pmid">15180989</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotheneder</surname><given-names>M</given-names></name><name><surname>Stakyte</surname><given-names>K</given-names></name><name><surname>van de Logt</surname><given-names>E</given-names></name><name><surname>Bartho</surname><given-names>JD</given-names></name><name><surname>Lammens</surname><given-names>K</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Alt</surname><given-names>A</given-names></name><name><surname>Kessler</surname><given-names>B</given-names></name><name><surname>Jung</surname><given-names>C</given-names></name><name><surname>Roos</surname><given-names>WP</given-names></name><name><surname>Steigenberger</surname><given-names>B</given-names></name><name><surname>Hopfner</surname><given-names>K-P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Cryo-EM structure of the Mre11-Rad50-Nbs1 complex reveals the molecular mechanism of scaffolding functions</article-title><source>Molecular Cell</source><volume>83</volume><fpage>167</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.12.003</pub-id><pub-id pub-id-type="pmid">36577401</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saldivar</surname><given-names>JC</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name><name><surname>Cimprich</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Publisher correction: The essential kinase ATR: ensuring faithful duplication of a challenging genome</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>622</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.116</pub-id><pub-id pub-id-type="pmid">29115300</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JC</given-names></name><name><surname>Gray</surname><given-names>MD</given-names></name><name><surname>Oshima</surname><given-names>J</given-names></name><name><surname>Loeb</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Characterization of Werner syndrome protein DNA helicase activity: directionality, substrate dependence and stimulation by replication protein A</article-title><source>Nucleic Acids Research</source><volume>26</volume><fpage>2879</fpage><lpage>2885</lpage><pub-id pub-id-type="doi">10.1093/nar/26.12.2879</pub-id><pub-id pub-id-type="pmid">9611231</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JC</given-names></name><name><surname>Lao</surname><given-names>Y</given-names></name><name><surname>Kamath-Loeb</surname><given-names>A</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name><name><surname>Loeb</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The N-terminal domain of the large subunit of human replication protein A binds to Werner syndrome protein and stimulates helicase activity</article-title><source>Mechanisms of Ageing and Development</source><volume>124</volume><fpage>921</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1016/s0047-6374(03)00164-7</pub-id><pub-id pub-id-type="pmid">14499497</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorrocks</surname><given-names>A-MK</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name><name><surname>Tsukada</surname><given-names>K</given-names></name><name><surname>Morrow</surname><given-names>CA</given-names></name><name><surname>Belblidia</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Vendrell</surname><given-names>I</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>Kessler</surname><given-names>BM</given-names></name><name><surname>Blackford</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>585</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20818-5</pub-id><pub-id pub-id-type="pmid">33500419</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>SY</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Crystal structure of the human rad9-hus1-rad1 clamp</article-title><source>Journal of Molecular Biology</source><volume>390</volume><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.05.028</pub-id><pub-id pub-id-type="pmid">19464297</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza-Fagundes</surname><given-names>EM</given-names></name><name><surname>Frank</surname><given-names>AO</given-names></name><name><surname>Feldkamp</surname><given-names>MD</given-names></name><name><surname>Dorset</surname><given-names>DC</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Rossanese</surname><given-names>OW</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A</article-title><source>Analytical Biochemistry</source><volume>421</volume><fpage>742</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2011.11.025</pub-id><pub-id pub-id-type="pmid">22197419</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spegg</surname><given-names>V</given-names></name><name><surname>Panagopoulos</surname><given-names>A</given-names></name><name><surname>Stout</surname><given-names>M</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Reginato</surname><given-names>G</given-names></name><name><surname>Imhof</surname><given-names>R</given-names></name><name><surname>Roschitzki</surname><given-names>B</given-names></name><name><surname>Cejka</surname><given-names>P</given-names></name><name><surname>Altmeyer</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Phase separation properties of RPA combine high-affinity ssDNA binding with dynamic condensate functions at telomeres</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>30</volume><fpage>451</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1038/s41594-023-00932-w</pub-id><pub-id pub-id-type="pmid">36894693</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suhasini</surname><given-names>AN</given-names></name><name><surname>Sommers</surname><given-names>JA</given-names></name><name><surname>Mason</surname><given-names>AC</given-names></name><name><surname>Voloshin</surname><given-names>ON</given-names></name><name><surname>Camerini-Otero</surname><given-names>RD</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name><name><surname>Brosh</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>FANCJ helicase uniquely senses oxidative base damage in either strand of duplex DNA and is stimulated by replication protein A to unwind the damaged DNA substrate in A strand-specific manner</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>18458</fpage><lpage>18470</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.012229</pub-id><pub-id pub-id-type="pmid">19419957</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syed</surname><given-names>A</given-names></name><name><surname>Tainer</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The MRE11-RAD50-NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair</article-title><source>Annual Review of Biochemistry</source><volume>87</volume><fpage>263</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-062917-012415</pub-id><pub-id pub-id-type="pmid">29709199</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneja</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Carrick</surname><given-names>R</given-names></name><name><surname>Uchiumi</surname><given-names>F</given-names></name><name><surname>Ott</surname><given-names>RD</given-names></name><name><surname>Gustafson</surname><given-names>E</given-names></name><name><surname>Podust</surname><given-names>VN</given-names></name><name><surname>Fanning</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A dominant-negative mutant of human DNA helicase B blocks the onset of chromosomal DNA replication</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>40853</fpage><lpage>40861</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208067200</pub-id><pub-id pub-id-type="pmid">12181327</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thada</surname><given-names>V</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ATR activation is regulated by dimerization of ATR activating proteins</article-title><source>Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100455</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100455</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tkáč</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Adhikary</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>JTF</given-names></name><name><surname>Gallo</surname><given-names>D</given-names></name><name><surname>Escribano-Díaz</surname><given-names>C</given-names></name><name><surname>Krietsch</surname><given-names>J</given-names></name><name><surname>Orthwein</surname><given-names>A</given-names></name><name><surname>Munro</surname><given-names>M</given-names></name><name><surname>Sol</surname><given-names>W</given-names></name><name><surname>Al-Hakim</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>Z-Y</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Borst</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>GW</given-names></name><name><surname>Gingras</surname><given-names>A-C</given-names></name><name><surname>Rottenberg</surname><given-names>S</given-names></name><name><surname>Masson</surname><given-names>J-Y</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>HELB Is a Feedback Inhibitor of DNA End Resection</article-title><source>Molecular Cell</source><volume>61</volume><fpage>405</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.12.013</pub-id><pub-id pub-id-type="pmid">26774285</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>hPrimpol1/CCDC111 is a human DNA primase-polymerase required for the maintenance of genome integrity</article-title><source>EMBO Reports</source><volume>14</volume><fpage>1104</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/embor.2013.159</pub-id><pub-id pub-id-type="pmid">24126761</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Singh</surname><given-names>TR</given-names></name><name><surname>Busygina</surname><given-names>V</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Wan</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>Meetei</surname><given-names>AR</given-names></name><name><surname>Lei</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Crystal Structures of RMI1 and RMI2, Two OB-Fold Regulatory Subunits of the BLM Complex</article-title><source>Structure</source><volume>18</volume><fpage>1159</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1016/j.str.2010.06.008</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Ballard</surname><given-names>CC</given-names></name><name><surname>Cowtan</surname><given-names>KD</given-names></name><name><surname>Dodson</surname><given-names>EJ</given-names></name><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Keegan</surname><given-names>RM</given-names></name><name><surname>Krissinel</surname><given-names>EB</given-names></name><name><surname>Leslie</surname><given-names>AGW</given-names></name><name><surname>McCoy</surname><given-names>A</given-names></name><name><surname>McNicholas</surname><given-names>SJ</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name><name><surname>Pannu</surname><given-names>NS</given-names></name><name><surname>Potterton</surname><given-names>EA</given-names></name><name><surname>Powell</surname><given-names>HR</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name><name><surname>Vagin</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Overview of the CCP4 suite and current developments</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>67</volume><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1107/S0907444910045749</pub-id><pub-id pub-id-type="pmid">21460441</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wold</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Replication protein A: A heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism</article-title><source>Annual Review of Biochemistry</source><volume>66</volume><fpage>61</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.66.1.61</pub-id><pub-id pub-id-type="pmid">9242902</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>RD</given-names></name><name><surname>Robins</surname><given-names>P</given-names></name><name><surname>Lindahl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts</article-title><source>Cell</source><volume>53</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(88)90491-6</pub-id><pub-id pub-id-type="pmid">3349527</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Shell</surname><given-names>SM</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells</article-title><source>Oncogene</source><volume>24</volume><fpage>4728</fpage><lpage>4735</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208674</pub-id><pub-id pub-id-type="pmid">15897895</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Sobeck</surname><given-names>A</given-names></name><name><surname>Bachrati</surname><given-names>CZ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>GW</given-names></name><name><surname>Hoatlin</surname><given-names>ME</given-names></name><name><surname>Hickson</surname><given-names>ID</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008a</year><article-title>RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>2843</fpage><lpage>2855</lpage><pub-id pub-id-type="doi">10.1101/gad.1708608</pub-id><pub-id pub-id-type="pmid">18923082</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Vaithiyalingam</surname><given-names>S</given-names></name><name><surname>Glick</surname><given-names>GG</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>Chazin</surname><given-names>WJ</given-names></name><name><surname>Cortez</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008b</year><article-title>The basic cleft of RPA70N binds multiple checkpoint proteins, including RAD9, to regulate ATR signaling</article-title><source>Molecular and Cellular Biology</source><volume>28</volume><fpage>7345</fpage><lpage>7353</lpage><pub-id pub-id-type="doi">10.1128/MCB.01079-08</pub-id><pub-id pub-id-type="pmid">18936170</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Bai</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><name><surname>Hang</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Structure and functional implications of the human rad9-hus1-rad1 cell cycle checkpoint complex</article-title><source>The Journal of Biological Chemistry</source><volume>284</volume><fpage>20457</fpage><lpage>20461</lpage><pub-id pub-id-type="doi">10.1074/jbc.C109.022384</pub-id><pub-id pub-id-type="pmid">19535328</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Raynard</surname><given-names>S</given-names></name><name><surname>Busygina</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of replication protein A in double holliday junction dissolution mediated by the BLM-Topo IIIα-RMI1-RMI2 protein complex</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>14221</fpage><lpage>14227</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.465609</pub-id><pub-id pub-id-type="pmid">23543748</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yariv</surname><given-names>B</given-names></name><name><surname>Yariv</surname><given-names>E</given-names></name><name><surname>Kessel</surname><given-names>A</given-names></name><name><surname>Masrati</surname><given-names>G</given-names></name><name><surname>Chorin</surname><given-names>AB</given-names></name><name><surname>Martz</surname><given-names>E</given-names></name><name><surname>Mayrose</surname><given-names>I</given-names></name><name><surname>Pupko</surname><given-names>T</given-names></name><name><surname>Ben-Tal</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Using evolutionary data to make sense of macromolecules with a “face-lifted” ConSurf</article-title><source>Protein Science</source><volume>32</volume><elocation-id>e4582</elocation-id><pub-id pub-id-type="doi">10.1002/pro.4582</pub-id><pub-id pub-id-type="pmid">36718848</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>LA</given-names></name><name><surname>Aramayo</surname><given-names>RJ</given-names></name><name><surname>Pokhrel</surname><given-names>N</given-names></name><name><surname>Caldwell</surname><given-names>CC</given-names></name><name><surname>Kaplan</surname><given-names>JA</given-names></name><name><surname>Perera</surname><given-names>RL</given-names></name><name><surname>Spies</surname><given-names>M</given-names></name><name><surname>Antony</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A structural and dynamic model for the assembly of Replication Protein A on single-stranded DNA</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>5447</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07883-7</pub-id><pub-id pub-id-type="pmid">30575763</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeom</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Investigation of the core binding regions of human Werner syndrome and Fanconi anemia group J helicases on replication protein A</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>14016</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-50502-8</pub-id><pub-id pub-id-type="pmid">31570747</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Pourmal</surname><given-names>S</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dna2 nuclease-helicase structure, mechanism and regulation by Rpa</article-title><source>eLife</source><volume>4</volume><elocation-id>e09832</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.09832</pub-id><pub-id pub-id-type="pmid">26491943</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chung</surname><given-names>WH</given-names></name><name><surname>Shim</surname><given-names>EY</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Ira</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sgs1 helicase and two nucleases Dna2 and Exo1 resect DNA double-strand break ends</article-title><source>Cell</source><volume>134</volume><fpage>981</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.08.037</pub-id><pub-id pub-id-type="pmid">18805091</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>L</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes</article-title><source>Science</source><volume>300</volume><fpage>1542</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.1126/science.1083430</pub-id><pub-id pub-id-type="pmid">12791985</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Shell</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses</article-title><source>Journal of Cellular Physiology</source><volume>208</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1002/jcp.20622</pub-id><pub-id pub-id-type="pmid">16523492</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81639.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shinohara</surname><given-names>Akira</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.07.14.500000" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.14.500000"/></front-stub><body><p>This important paper advances our understanding of how a eukaryotic single-stranded DNA binding protein, Replication protein-A (RPA) interacts with multiple proteins in DNA transactions. The author provided compelling structure information on an OB-fold called RPA70N (or DBD-F) with 8 different peptides from various DNA metabolisms, which is complemented by in vivo studies. This paper will be of interest to researchers in DNA replication, recombination, and repair as well as structural biologists interested in a weak protein-protein interaction.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81639.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shinohara</surname><given-names>Akira</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Shinohara</surname><given-names>Akira</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035t8zc32</institution-id><institution>Osaka University</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.07.14.500000">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.07.14.500000v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Structural characterization of human RPA70N association with DNA damage response proteins&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Akira Shinohara as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Volker Dötsch as the Senior Editor.</p><p>Based on reviews and discussions with reviewers, we do appreciate that your structural and biochemical results are very important to understand how RPA binds to more than 30 different proteins involved in DNA transactions and applaud the breadth of the work and the high quality of the structures. However, we are very sorry that we can not be more positive about publishing the current version of the paper. Mainly, as you acknowledge, in most of your results, similar structural studies on RPA70N to other proteins (such as p53, ATRIP/Ddc2, PrimPol, DNA2) have been reported. The results in the current version constitute only a limited advance in our understanding of how RPA binds to different binding partners.</p><p>On the other hand, if you can provide direct in vitro evidence by biochemical analyses using full-length RPA and a full-length BLM or RMI1 that an RPA-binding protein promotes or changes the oligomerization of RPA in solution or on ssDNA, the paper would provide new insights into RPA70N-interaction with other proteins.</p><p>The text would also have to be re-written substantially, so that it flows more logically and through referring to other publications and revising figures.</p><p>Essential revisions:</p><p>Please determine the interaction between both RPA and RPA-binding proteins by using full-length wild-type and mutant proteins in vitro. Given that BLMp1, BLMp2 and RMI1p could induce the oligomer formation (dimerization) of RPAs, it would be nice to focus on the binding of either BLM or RMI1 to RPA. Importantly, it is highly recommended to quantify a molar ratio of BLM/RMI1 to RPA-the authors may use gel-filtration (you may need the cross-linking to stabilize the binding) or quantitative pull-down assays or others such as low-resolution cryoEM analysis.</p><p>1. We do not ask you to do in vivo experiments (as pointed out by Reviewers #1 and #3). However, it is very important to search for literature for in vivo studies to complement your structural studeis and to refer to them in the text in an organized manner.</p><p>2. As reviewers #2 and #3 pointed out, you need to add more explanation of your experiment design and results and to discuss your findings logically. And also, you need to reformat your figures by showing RPA-peptides interaction in the same way (see comments by #3 reviewer).</p><p>3. Reviewer #3 provided a good example of how to show images of your 3D structure in your Figures. Please use it during your revision.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The conclusion in the paper is well supported by the results described in the paper. However, given the binding affinity of RPA70N to various peptides is very weak with Kd of 10-18 uM, it is very important to test whether the interactions described in the paper are functionally relevant in vivo. In particular, the authors need to carry out in vivo and/or functional analyses of the proteins with substitution/deletion in the RPA70N-binding motif in a full-length protein such as HelB or WRN.</p><p>1. The authors nicely showed different conformation of peptides bound to RPA70N. On the other hand, the authors did not mention the conformational change(s) of the RPA70N domain by itself upon the binding of the peptides. In this line, the authors nicely showed distinct conformational changes between two RPA70Ns by the binding to either BLMp1 or BLMp2 (Figure 3). It is critical to mention any structural change of a single RPA70N domain upon the binding.</p><p>2. It is also important to check the role of RPA70N-binding motifs in various proteins in vivo. The previous findings showed the role of RPA70N binding motifs in human BLM, RMI, and yeast ATRIP/Ddc1 (Deshpande et al. 2017; Shorrocks et al. 2020). These should be mentioned in the text more clearly. Much more importantly, the authors should check the binding motifs of human HelB and WRN in vivo. Different from BLM-RMI1(-TOPIII-RMI2), HelB and WRN bear only one weak RPA70N binding motif. Given the Kd of the interaction, it is very unlikely that this binding motif in the helicases is sufficient to make stable interaction with RPA in cells.</p><p>3. In the same line, it is very critical to check the binding of some full-length proteins and mutant forms of the proteins to RPA70N in vitro.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The structures are of high quality and provide details of the interactions. Multiple binding modes are observed based on the peptide in question. These agree with binding modes previously observed for interactors with OB-F. ITC experiments and mutagenesis are used to validate the interactions and provide quantitative information about the interactions. This study adds to the wealth of structural information available on RPA protein interactions.</p><p>The study confirms the two binding surfaces formerly identified and show that the peptides studies use these regions for interactions. The authors posit that kinking, tilting, polarity, and dimerization are features used to accommodate the peptide into the binding pockets in OB-F.</p><p>Another prominent feature highlighted by the authors is one of multivalency: where multiple RPA molecules bound on DNA could drive recruitment dimers of the interacting proteins. In this scenario, peptides can be shared between two RPA molecules and a string of RPA can be promoted through such interactions.</p><p>While these findings are interesting, this reviewer believes that these studies do not add substantially to what is already known from existing structures of OB-F protein interactions. The two binding surfaces are already established. The different modes of peptide interactions have been observed in other such structural studies.</p><p>If the authors want to build on the multivalent interactions, these results need to be substantiated with the full length proteins. For example, can the authors show that full length RPA oligomeric assemblies are driven by their target interactor? Another issue is the assumption here that the OB-F domain is freely floating around in solution. This is an incorrect assumption as OB-F interacts with other regions within the rest of the protein. Thus, the protein interactions investigated here will likely have contributions from other regions of RPA. Thus, the models proposed here that OB-F are exclusively coordinating these RPA-protein interactions are incomplete.</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>The authors have presented beautiful structures of RPA bound to peptides derived from interacting partners. The structural studies are supported by biochemical binding assays using ~22 residue peptides corresponding to wild type and carefully selected mutants to show binding. The Discussion of the paper is disappointing as it is a list of published papers and does not delineate the implications of the insight provided. So as its stands now this is a paper with beautiful structures but the implications of the data are poor. This has to be addressed. Figure 6 was challenging to sort out partially because the colour scheme is tough to see.</p><p>So how can this paper be improved? First, all the RPA70-peptide images are in different orientations so it is difficult to see where the peptides bind and to make comparisons between the different structures. In my opinion, a common orientation should be settled upon to indicate where the peptides bind. For example, as OB-folds and SH3 domains are known to be structurally similar (Agrawal, V., and Kishan, R. K. (2001) Functional evolution of two subtly different (similar) folds, BMC Struct Biol 1, 5), and SH3 domains bind PXXP-ligands in the pocket or mouth between the RT- and nSrc loops, how about an orientation that reflects this. For example:</p><p>Here I have used the OB-fold of RPA70 viewed from the side and top, and the HelB interacting residues. The position of the HelB peptide could be indicated for example in blue with orientation labeled. By using this type of approach, one can easily see where peptides bind, can they compete for binding if sites overlap, and implications of different orientations of binding can be suggested. For example, does one orientation stabilize binding to ssDNA and another enhance dissociation of RPA for example? This is important to discuss as the implication for regulation of RPA and interacting partner activity is important.</p><p>Then the authors do not make sufficient comparisons between the peptide binding pockets and again a comparison using the above figure or some other schematic should be presented.</p><p>Next, are there any mutations in either RPA70 or the interacting partners that are known to abolish function in vivo? And or be disease-related? This can further support the structural data.</p><p>How do the structural data enhance or disagree with the current biochemical data? This has been alluded to in the text but needs further elaboration.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81639.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Please determine the interaction between both RPA and RPA-binding proteins by using full-length wild-type and mutant proteins in vitro. Given that BLMp1, BLMp2 and RMI1p could induce the oligomer formation (dimerization) of RPAs, it would be nice to focus on the binding of either BLM or RMI1 to RPA. Importantly, it is highly recommended to quantify a molar ratio of BLM/RMI1 to RPA-the authors may use gel-filtration (you may need the cross-linking to stabilize the binding) or quantitative pull-down assays or others such as low-resolution cryoEM analysis.</p></disp-quote><p>We thank the editor for the helpful suggestions. The BTR complex has four components BLM, TOP3a, RMI1 and RIM2 in a 2:2:2:2 ratio (Hodson et al., 2022). BLM and TOP3a are relatively large proteins with long disordered regions, we failed to obtain the intact BTR complex despite following the procedures used by Hodson et al. We’ll continue working on the preparation of full-length BTR complex. We hope that in the future we could examine the binding of RPA with full-length target proteins. Recently Spegg et al. showed that RPA has a strong propensity to assemble into dynamic condensates (phase separation), which is likely driven by RPA2 and could be stimulated by ssDNA binding (Spegg et al., 2023). More importantly, they demonstrated that RPA condensation enhances interactions with the BTR complex. The multivalent interaction we observed in the crystal structures could contribute significantly to this process in theory. Further studies with multiple approaches would be needed to delineate whether/how RPA70N functions in this dynamic process.</p><disp-quote content-type="editor-comment"><p>1. We do not ask you to do in vivo experiments (as pointed out by Reviewers #1 and #3). However, it is very important to search for literature for in vivo studies to complement your structural studies and to refer to them in the text in an organized manner.</p></disp-quote><p>We thank the editor for the supportive comment. To consolidate our findings, we carried out confocal imaging analysis to investigate the colocalization of RPA with WT or mutant partner proteins in HeLa cells. We also performed coimmunoprecipitation experiments to investigate the impact of mutation of interface residues on RPA-partner protein association. In general, our results agree well with previous findings; in addition, due to the availability of precise structure information, we didn’t need to use deletion mutations. When describing our results, we paid particular attention to comparing our findings with previous studies.</p><disp-quote content-type="editor-comment"><p>2. As reviewers #2 and #3 pointed out, you need to add more explanation of your experiment design and results and to discuss your findings logically. And also, you need to reformat your figures by showing RPA-peptides interaction in the same way (see comments by #3 reviewer).</p></disp-quote><p>We thank the editor for the very helpful comment. As suggested, we’ve added new figures to help explain the background and experiment design (new Figure 1A-1E, Figure 1—figure supplement 1A and 1B). We’ve also displayed structures determined in this study in a uniform way (new Figure 1F-1N). In addition, we summarized some of the structure information in Figure 10A for comparison.</p><disp-quote content-type="editor-comment"><p>3. Reviewer #3 provided a good example of how to show images of your 3D structure in your Figures. Please use it during your revision.</p></disp-quote><p>We thank the editor for the great suggestion. As suggested, we’ve added new figures to show RPA-peptide interaction in the same way (new Figure 1F-1N). For clarity, some figures displaying specific side-chain interactions were rotated to different degrees, in these figures we labeled L12 and L45 loops to mark the viewing direction.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The conclusion in the paper is well supported by the results described in the paper. However, given the binding affinity of RPA70N to various peptides is very weak with Kd of 10-18 uM, it is very important to test whether the interactions described in the paper are functionally relevant in vivo. In particular, the authors need to carry out in vivo and/or functional analyses of the proteins with substitution/deletion in the RPA70N-binding motif in a full-length protein such as HelB or WRN.</p><p>1. The authors nicely showed different conformation of peptides bound to RPA70N. On the other hand, the authors did not mention the conformational change(s) of the RPA70N domain by itself upon the binding of the peptides. In this line, the authors nicely showed distinct conformational changes between two RPA70Ns by the binding to either BLMp1 or BLMp2 (Figure 3). It is critical to mention any structural change of a single RPA70N domain upon the binding.</p></disp-quote><p>We thank the reviewer for raising this important question. Superposition of the 9 structures determined in this study with apo RPA70N showed that most of the Ca atoms of RPA70N were at nearly identical positions, with RMSD values smaller than 0.3 Å. The L12 and L45 regions displayed some conformational changes to accommodate different peptides (Figure 10B). Overall, it appears that the interaction of RPA70N with partner protein motifs relies on the movement of side chains of the conserved positively-charged and hydrophobic residues as illustrated in the main figures. We added the text to the discussion session (line #417-422).</p><disp-quote content-type="editor-comment"><p>2. It is also important to check the role of RPA70N-binding motifs in various proteins in vivo. The previous findings showed the role of RPA70N binding motifs in human BLM, RMI, and yeast ATRIP/Ddc1 (Deshpande et al. 2017; Shorrocks et al. 2020). These should be mentioned in the text more clearly. Much more importantly, the authors should check the binding motifs of human HelB and WRN in vivo. Different from BLM-RMI1(-TOPIII-RMI2), HelB and WRN bear only one weak RPA70N binding motif. Given the Kd of the interaction, it is very unlikely that this binding motif in the helicases is sufficient to make stable interaction with RPA in cells.</p></disp-quote><p>We thank the reviewer for the insightful suggestions. To consolidate our findings, we carried out confocal imaging analysis to investigate the colocalization of RPA with WT or mutant partner proteins in HeLa cells. We also performed coimmunoprecipitation experiments to investigate the impact of mutation of interface residues on RPA-partner protein association. Our in vivo results confirmed that the interface residues we uncovered from structural studies are critical for RPA-partner protein interaction. Although HelB only has one RPA binding motif, its affinity (4 µM) is relatively high among RPA70N binding proteins. Transient transfection of HelB-EGFP into HeLa cells resulted in bright HelB and RPA foci that colocalized in nearly 80% of cells (Figure 2H-2J,), mutation of the HelB residues involved in RPA70 binding led to much fewer foci in cells. WRN has two identical RPA binding motifs, for each motif the affinity is around 11.6 µM. Transient transfection of EGFP-WRN into HeLa cells resulted in obvious WRN and RPA foci, most of which were colocalized, especially after camptothecin (CPT) or hydroxyurea (HU) treatment (Figure 5H-5K). Transfection of a double mutant EGFP-WRN resulted in less WRN foci formation and in most cells endogenous RPA no longer formed foci, highlighting the interplay between WRN and RPA. We believe that individual RPA70 has a relatively low affinity for target proteins to prevent unwanted DNA damage response. DNA damage induced ssDNA exposure enriches RPA onto ssDNA, which would greatly enhance RPA binding to partner proteins, much like streptavidin tetramer has a higher affinity for biotin than a streptavidin monomer.</p><disp-quote content-type="editor-comment"><p>3. In the same line, it is very critical to check the binding of some full-length proteins and mutant forms of the proteins to RPA70N in vitro.</p></disp-quote><p>We thank the reviewer for the suggestion. Most of the RPA binding motifs are located in the disordered and flexible regions of the partner proteins. We’ve encountered difficulties in preparing intact full-length partner proteins. Instead, we performed coimmunoprecipitation analysis with full-length proteins, the results showed that mutation of interface residues reduced their binding to RPA trimer (new Figure 2K, 3N, 4H, 5L, 6K, 7E, 8F, 9H).</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The structures are of high quality and provide details of the interactions. Multiple binding modes are observed based on the peptide in question. These agree with binding modes previously observed for interactors with OB-F. ITC experiments and mutagenesis are used to validate the interactions and provide quantitative information about the interactions. This study adds to the wealth of structural information available on RPA protein interactions.</p><p>The study confirms the two binding surfaces formerly identified and show that the peptides studies use these regions for interactions. The authors posit that kinking, tilting, polarity, and dimerization are features used to accommodate the peptide into the binding pockets in OB-F.</p><p>Another prominent feature highlighted by the authors is one of multivalency: where multiple RPA molecules bound on DNA could drive recruitment dimers of the interacting proteins. In this scenario, peptides can be shared between two RPA molecules and a string of RPA can be promoted through such interactions.</p><p>While these findings are interesting, this reviewer believes that these studies do not add substantially to what is already known from existing structures of OB-F protein interactions. The two binding surfaces are already established. The different modes of peptide interactions have been observed in other such structural studies.</p></disp-quote><p>We thank the reviewer for the insightful comments. It is true that the groove and the side pocket have been described by previous studies on p53 and DNA2. However, there are many differences as to how each protein interacts with RPA70N. We summarized some of the features in the new Figure 10A. For example, in the case of p53, the C-terminus end of the p53 peptide binds to the groove, the N-terminus end binds to the side pocket in another RPA70N. BLMp1 and RMI1 bind to RPA70N similar to p53, however their peptide direction is reversed compared to p53. In the case of DNA2, one DNA2 peptide binds both the groove and the side pocket in one RPA70N molecule; RAD9 does the same, but again the peptide direction is reversed compared to DNA2. In the case of PrimPol or yeast Ddc2, only the groove is involved in binding, ATRIP, MRE11 and ETAA1 use similar modes to bind RPA70N as PrimPol or Ddc2, nevertheless they differ a lot as to the specific side-chain arrangements since their sequences are divergent (Figure 1figure supplement 1A). In this study we’ve greatly expanded the structure information regarding RPA70N protein interactions through a systematic approach.</p><disp-quote content-type="editor-comment"><p>If the authors want to build on the multivalent interactions, these results need to be substantiated with the full length proteins. For example, can the authors show that full length RPA oligomeric assemblies are driven by their target interactor? Another issue is the assumption here that the OB-F domain is freely floating around in solution. This is an incorrect assumption as OB-F interacts with other regions within the rest of the protein. Thus, the protein interactions investigated here will likely have contributions from other regions of RPA. Thus, the models proposed here that OB-F are exclusively coordinating these RPA-protein interactions are incomplete.</p></disp-quote><p>We thank the reviewer for the helpful suggestions. We agree that it would be beneficial to interrogate the effect of multivalent interactions with full-length proteins. However, many of the proteins involved in this study are large protein complexes with disordered regions, it would take tremendous effort to assemble and purify these complexes in full-length form. To consolidate our findings, we expressed EGFP or FLAG-tagged partner proteins in HeLa cells to see whether they could promote RPA foci formation. HelB, BLM, WRN, ATRIP and ETTA1 formed a great number of foci and colocalized with endogenous RPA (stained with antibodies against RPA2), which is further stimulated by CPT or HU treatment (new Figure 2H-2J, 3J-3M, 5H-5K, 6F-6J, 9D-9G). Mutation of interface residues significantly weakens the foci formation and colocalization (new Figure 2H-2J, 3J-3M, 5H-5K, 6F-6J, 9D-9G). RMI1, MRE11 and RAD9 didn’t form distinct foci, but still colocalized with RPA to different degrees, which was weakened by interface mutations (new Figure 4G, 7D, 8E). Thus, it’s possible that ssDNA enriches RPA on the damage site which promotes its association with partner proteins; at the same time, RPA70N binding to partner proteins with multivalent sites in turn promotes RPA oligomeric assembly. We’ve added the text to the discussion.</p><p>We agree with the reviewer that 70N/OB-F interacts with other parts of the RPA trimer and other regions of RPA also mediate interactions with many DNA damage response proteins, which is a highly complex and dynamic process (Caldwell and Spies, 2020). For example, ETAA1 has two RPA binding motifs, one for RPA70N, and the other for RPA32C.</p><p>For this study we focused on RPA70N interacting motifs, to the best of our knowledge, when RPA binds to ssDNA, the RPA70N domain is quite dynamic (Caldwell and Spies, 2020; Deshpande et al., 2017; Kuppa et al., 2022; Pokhrel et al., 2019; Yates et al., 2018). The model we presented in old Figure 6 has been replaced with Figure 10—figure supplement 1, our intention is to explain the possible role of RPA70N in DNA damage response protein recruitment with a simplified model. We’ve now acknowledged the limitations of our study in the discussion (line #485-487).</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>The authors have presented beautiful structures of RPA bound to peptides derived from interacting partners. The structural studies are supported by biochemical binding assays using ~22 residue peptides corresponding to wild type and carefully selected mutants to show binding. The Discussion of the paper is disappointing as it is a list of published papers and does not delineate the implications of the insight provided. So as its stands now this is a paper with beautiful structures but the implications of the data are poor. This has to be addressed. Figure 6 was challenging to sort out partially because the colour scheme is tough to see.</p><p>So how can this paper be improved? First, all the RPA70-peptide images are in different orientations so it is difficult to see where the peptides bind and to make comparisons between the different structures. In my opinion, a common orientation should be settled upon to indicate where the peptides bind. For example, as OB-folds and SH3 domains are known to be structurally similar (Agrawal, V., and Kishan, R. K. (2001) Functional evolution of two subtly different (similar) folds, BMC Struct Biol 1, 5), and SH3 domains bind PXXP-ligands in the pocket or mouth between the RT- and nSrc loops, how about an orientation that reflects this. For example:</p><p>Here I have used the OB-fold of RPA70 viewed from the side and top, and the HelB interacting residues. The position of the HelB peptide could be indicated for example in blue with orientation labeled. By using this type of approach, one can easily see where peptides bind, can they compete for binding if sites overlap, and implications of different orientations of binding can be suggested. For example, does one orientation stabilize binding to ssDNA and another enhance dissociation of RPA for example? This is important to discuss as the implication for regulation of RPA and interacting partner activity is important.</p></disp-quote><p>We sincerely appreciate the reviewer for the detailed advice to improve the presentation of the figures. As suggested, we’ve now displayed the structures determined in this study in a uniform way in new Figure 1F-1N, we’ve also labeled L12 and L45 in all figures as a reference for direction. In addition, we summarized some of the binding features in Figure 10A for comparison. RPA binds ssDNA in a strict 5’-3’ direction (Fan and Pavletich, 2012; Kolpashchikov et al., 2001) which is important for positioning the excision repair nucleases XPG, ERCC1–XPF as well as DNA2 on the DNA (de Laat et al., 1998; Zhou et al., 2015). For RPA70N the peptide binds in either direction (Figure 10A), we currently don’t have any data to show the effect of the peptide binding direction, we’ll investigate this interesting question in future studies.</p><disp-quote content-type="editor-comment"><p>Then the authors do not make sufficient comparisons between the peptide binding pockets and again a comparison using the above figure or some other schematic should be presented.</p></disp-quote><p>We thank the reviewer for pointing this out. We’ve added more figures to show the binding pockets (new Figure 1B, 1C, 1E) and we’ve also compared RPA70N from different structures to show its conformational changes (Figure 10B).</p><disp-quote content-type="editor-comment"><p>Next, are there any mutations in either RPA70 or the interacting partners that are known to abolish function in vivo? And or be disease-related? This can further support the structural data.</p></disp-quote><p>We thank the reviewer for the excellent suggestion. Many of the DNA damage response proteins are related to cancer or rare genetic diseases like Bloom syndrome, Werner syndrome. We’ve checked the COSMIC and cBioPortal databases, R31 in RPA70N is mutated to H or C in some cancer patients, which might be related to its role in protein protein interaction. With ITC, we showed the R31H mutation reduced the interaction between RPA70N and interacting peptides (Figure 2—figure supplement 1G, Figure 3figure supplement 2F, Figure 4—figure supplement 1E, Figure 5—figure supplement 1E, Figure 8—figure supplement 1C, Figure 9—figure supplement 1C). Currently, we don’t know how this mutation affects cells, which warrants more investigation in future studies. We didn’t find meaningful point mutations specifically related to the RPA70N binding motifs in BLM or WRN from Bloom syndrome or Werner syndrome patients. To support the structural data, we carried out confocal imaging analysis to investigate the colocalization of RPA with WT or mutant partner proteins in HeLa cells. We’ve also performed coimmunoprecipitation experiments to investigate the impact of mutation of interface residues on RPA-partner protein association. We now show that the interface residues we’ve identified in the structures are crucial for the recruitment of DNA damage response proteins to the RPA foci and many of the partner proteins are able to promote RPA foci formation, which is closely linked to DNA damage response.</p><disp-quote content-type="editor-comment"><p>How do the structural data enhance or disagree with the current biochemical data? This has been alluded to in the text but needs further elaboration.</p></disp-quote><p>We thank the reviewer for raising this important question. In general, we believe the structural data enhances the understanding and application of the current biochemical data. First, our systematic structural characterization of RPA70N-target protein interaction provides a molecular basis for partner protein recruitment by RPA70N and rich information for the DNA damage response field. For example, with structure-guided mutations it is possible to precisely disrupt the interaction between RPA70N and target proteins without causing unwanted side effects. Second, through systematic comparison, we show that RPA70N utilizes its two binding interfaces in various modes. The multivalent interaction we’ve observed in the crystal structures could contribute significantly to the condensation-driven DNA damage response processes as means for rapid signal amplification. Third, our structure information helps to understand how a small domain like RPA70N recognizes diverse target sequences with low sequence homology, which is still challenging for algorithms to predict accurately. Fourth, RPA proteins are often overexpressed in cancer cells due to increased replication stress, great efforts have been made to develop inhibitors to reduce RPA-target protein association to curtail cancer growth and increase the efficacy of chemotherapy drugs (Glanzer et al., 2013; Glanzer et al., 2014). The structural data presented in this study would definitely benefit this process.</p><p>References:</p><p>Bochkareva, E., Kaustov, L., Ayed, A., Yi, G.S., Lu, Y., Pineda-Lucena, A., Liao, J.C., Okorokov, A.L., Milner, J., Arrowsmith, C.H., and Bochkarev, A. (2005). Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc Natl Acad Sci U S A <italic>102</italic>, 1541215417. 10.1073/pnas.0504614102.</p><p>Caldwell, C.C., and Spies, M. (2020). Dynamic elements of replication protein A at the crossroads of DNA replication, recombination, and repair. Crit Rev Biochem Mol Biol <italic>55</italic>, 482-507. 10.1080/10409238.2020.1813070.</p><p>de Laat, W.L., Appeldoorn, E., Sugasawa, K., Weterings, E., Jaspers, N.G., and Hoeijmakers, J.H. (1998). DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair. Genes Dev <italic>12</italic>, 2598-2609. 10.1101/gad.12.16.2598.</p><p>Deshpande, I., Seeber, A., Shimada, K., Keusch, J.J., Gut, H., and Gasser, S.M. (2017). Structural Basis of Mec1-Ddc2-RPA Assembly and Activation on Single-Stranded DNA at Sites of Damage. Mol Cell <italic>68</italic>, 431-445 e435. 10.1016/j.molcel.2017.09.019.</p><p>Fan, J., and Pavletich, N.P. (2012). Structure and conformational change of a replication protein A heterotrimer bound to ssDNA. Genes Dev <italic>26</italic>, 2337-2347. 10.1101/gad.194787.112.</p><p>Feldkamp, M.D., Frank, A.O., Kennedy, J.P., Patrone, J.D., Vangamudi, B., Waterson, A.G., Fesik, S.W., and Chazin, W.J. (2013). Surface reengineering of RPA70N enables cocrystallization with an inhibitor of the replication protein A interaction motif of ATR interacting protein. Biochemistry <italic>52</italic>, 65156524. 10.1021/bi400542z.</p><p>Glanzer, J.G., Carnes, K.A., Soto, P., Liu, S., Parkhurst, L.J., and Oakley, G.G. (2013). A small molecule directly inhibits the p53 transactivation domain from binding to replication protein A. Nucleic Acids Res <italic>41</italic>, 2047-2059. 10.1093/nar/gks1291.</p><p>Glanzer, J.G., Liu, S., Wang, L., Mosel, A., Peng, A., and Oakley, G.G. (2014). RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res <italic>74</italic>, 5165-5172. 10.1158/00085472.CAN-14-0306.</p><p>Guilliam, T.A., Brissett, N.C., Ehlinger, A., Keen, B.A., Kolesar, P., Taylor, E.M., Bailey, L.J., Lindsay, H.D., Chazin, W.J., and Doherty, A.J. (2017). Molecular basis for PrimPol recruitment to replication forks by RPA. Nat Commun <italic>8</italic>, 15222. 10.1038/ncomms15222.</p><p>Hodson, C., Low, J.K.K., van Twest, S., Jones, S.E., Swuec, P., Murphy, V., Tsukada, K., Fawkes, M., Bythell-Douglas, R., Davies, A., et al. (2022). Mechanism of Bloom syndrome complex assembly required for double Holliday junction dissolution and genome stability. Proc Natl Acad Sci U S A <italic>119</italic>. 10.1073/pnas.2109093119.</p><p>Kolpashchikov, D.M., Khodyreva, S.N., Khlimankov, D.Y., Wold, M.S., Favre, A., and Lavrik, O.I. (2001). Polarity of human replication protein A binding to DNA. Nucleic Acids Res <italic>29</italic>, 373-379.10.1093/nar/29.2.373.</p><p>Kuppa, S., Deveryshetty, J., Chadda, R., Mattice, J.R., Pokhrel, N., Kaushik, V., Patterson, A., Dhingra, N., Pangeni, S., Sadauskas, M.K., et al. (2022). Rtt105 regulates RPA function by configurationally stapling the flexible domains. Nat Commun <italic>13</italic>, 5152. 10.1038/s41467-022-32860-6.</p><p>Pokhrel, N., Caldwell, C.C., Corless, E.I., Tillison, E.A., Tibbs, J., Jocic, N., Tabei, S.M.A., Wold, M.S., Spies, M., and Antony, E. (2019). Dynamics and selective remodeling of the DNA-binding domains of RPA. Nat Struct Mol Biol <italic>26</italic>, 129-136. 10.1038/s41594-018-0181-y.</p><p>Souza-Fagundes, E.M., Frank, A.O., Feldkamp, M.D., Dorset, D.C., Chazin, W.J., Rossanese, O.W., Olejniczak, E.T., and Fesik, S.W. (2012). A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem <italic>421</italic>, 742-749.10.1016/j.ab.2011.11.025.</p><p>Spegg, V., Panagopoulos, A., Stout, M., Krishnan, A., Reginato, G., Imhof, R., Roschitzki, B., Cejka, P., and Altmeyer, M. (2023). Phase separation properties of RPA combine high-affinity ssDNA binding with dynamic condensate functions at telomeres. Nat Struct Mol Biol <italic>30</italic>, 451-462. 10.1038/s41594023-00932-w.</p><p>Yates, L.A., Aramayo, R.J., Pokhrel, N., Caldwell, C.C., Kaplan, J.A., Perera, R.L., Spies, M., Antony, E., and Zhang, X. (2018). A structural and dynamic model for the assembly of Replication Protein A on single-stranded DNA. Nat Commun <italic>9</italic>, 5447. 10.1038/s41467-018-07883-7.</p><p>Zhou, C., Pourmal, S., and Pavletich, N.P. (2015). Dna2 nuclease-helicase structure, mechanism and regulation by Rpa. <italic>eLife 4</italic>. 10.7554/<italic>eLife</italic>.09832.</p></body></sub-article></article>